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Hepatocellular Carcinoma (HCC) is the most common primary liver tumor and  is a 
major cause of cancer related death worldwide with few avenues of treatment that benefit 
patients. There are many causes of HCC making the cancer difficult to treat as a homogenous 
disease. Many molecular pathways are deregulated during the onset of hepatocarcinogenesis, and 
one commonly activated signaling cascade in HCC is the Wnt/β-catenin pathway. β-Catenin 
plays multiple roles in cellular processes from maintenance of cellular adhesions to regulating 
regenerative signals required for the liver to grow. In cancer, β-catenin signaling is aberrantly 
regulated and has now been shown to play roles in tumor cell proliferation, survival and 
metabolism contributing to disease progression. Knowing the prevalence and importance of β-
catenin in HCC, it is critical to develop targeted, personalized therapeutics which may impact 
multiple aspects of tumor biology. Here, we have identified several different avenues that target 
active Wnt signaling. We demonstrate the importance of computational biology to identify novel 
small molecules (SMs) to target β-catenin signaling. SM treatment results in decreased β-catenin 
signaling leading to decreases in downstream targets affecting HCC growth and survival. We 
also utilized antisense treatments which target β-catenin at the genetic level decreasing β-catenin 
protein expression and leading to subsequent cell death and decrease in tumor burden. 
Additionally, we identified angiogenesis as a notable event regulated by Wnt/β-catenin signaling 
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In fact, inhibiting Wnt signaling in HCC cells led to reduced production of pro-angiogenic 
secreted factors which in turn inhibited angiogenic characteristics in tumor associated endothelial 
cells. Our studies validate the significance of targeting β-catenin in HCC that should lead to 
notable effects on tumor growth and development. With the current studies providing the final 
proof-of-concept, we now believe that β-catenin directed therapies may in fact be plausible, and 
have potential clinical implications. 
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1.0  INTRODUCTION 
Among the leading causes of morbidity and mortality worldwide, cancer is one of the top 
10 non-communicable diseases according to the World Health Organization (WHO). Cancer is 
the uncontrolled growth of a mass of cells which lead to debilitating inhibition of normal body 
functions. Cancer itself is characterized as poorly differentiated, and tends to resemble a state in 
development where cells and tissue are constantly in a proliferative status. Research has shown 
that depending on the geographical and economic environments the incidences and mortality 
rates of different types of cancer differs significantly (1, 2). Depending on the type of 
environment, oncogenesis can be dictated by a number of external factors such as cigarette 
smoke, ultraviolet light exposure, or even chronic viral infections. Current treatment methods 
consist of chemotherapy, hormone therapy, surgery and targeted therapies.  
Targeted therapies are starting to become widely accepted as the most effective method 
of therapy for cancer. This belief stems from the presence of specific genetic mutations affecting 
proteins that normally regulate cell cycle progression or proliferation, such as p53, β-catenin, or 
c-myc, which lead to uncontrolled cell growth resulting in oncogenesis. The heterogeneous 
nature of each cancer makes it very difficult for developing a “magic bullet” which could treat 
every cancer. Even within one type of cancer, such as breast cancer, there can exist different 
mutations yielding a specific phenotype. It is entirely possible for one patient to present breast 
cancer positive for BRCA1/2 mutations, but another patient without these mutations therefore a 
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therapy targeting BRCA1/2 mutations would only benefit one of the two.  Understanding the 
molecular mechanisms behind the heterogeneous development of the same type of cancer is 
critical in order to develop specific targeted therapies. Thus current research suggests that 
identifying and targeting multiple activated oncogenic pathways in specific cancers is the next 
step in revolutionizing cancer therapeutics. 
1.1 CANCER EPIDEMIOLOGY 
1.1.1 Worldwide cancer burden 
In 2008 the global population reached 6.7 billion. Of these 6.7 billion people in the 
world, 12.7 million had cancer (1, 2). There are many causes for the incidence of cancer 
worldwide, which consist of the increased rates of smoking, alcoholism, as well as the 
Westernization of many cultural diets. Breast and lung cancers are the most frequently diagnosed 
cancers and causes of death in women and men worldwide (1, 2). The dichotomy is observed 
when comparing the incidence rates of different types of cancer between developed and 
developing nations. In Westernized countries the most frequently diagnosed cancers in both 
males and females are colorectal and lung cancers (1, 2). Cervical and lung cancers in females, 
and stomach and liver cancers in males are the most commonly diagnosed diseases in developing 
nations (1, 2). These statistics show that risk factors may vary depending on the environment. 
Underdeveloped countries tend to be more susceptible to cancers caused by infections such as 
stomach and liver cancers, whereas Westernized nations are more prone to cancers caused by 
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habits like smoking, inactivity and alcoholism, which have been associated with 2 to 5 times 
higher rate for prostate, colorectal, breast and lung cancers in developed countries (1, 2).  
1.1.2 Cancer related deaths worldwide 
There were a total of 7.6 million cancer deaths in 2008 worldwide (1, 2). At 64%, the 
majority of cancer related deaths occurred in the developing world indicating a lack in medical 
resources needed to manage the disease burden in these areas (1, 2). Divergence in death rates 
associated with cancer in developing versus developed nations clearly highlights the differences 
in quality of oncology care (1, 2). Breast cancer is among the most frequently diagnosed cancer 
and leading cause of death in females worldwide accounting for 23% of total cancer cases and 
14% of all deaths followed by lung cancer at 13% and then colorectal cancer at 9% (1, 2). In 
men, the leading cause of cancer related death is lung cancer at 23% followed by liver (11%) and 
stomach (11%) cancers (1, 2).  
1.1.3 Four most common cancers: Breast, Colorectal, Lung, and Liver  
Breast cancer accounts for 23% of all new diagnoses and 14% of all cancer related deaths 
in 2008 (1, 2). The difference in incidence rates of breast cancer between developed and 
underdeveloped nations, 66.4 cases per 100,000 people compared to 27.3 cases per 100,000 
respectively, are high largely due to differences in reproductive and hormonal factors stemming 
from such things as menstrual history, nulliparity, postmenopausal hormone therapy, oral 
contraceptives, and late age at first birth, as well as the availability of early detection services (3-
5). In developed nations early detection methods are much more common (5). Early detection 
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more often than not increases the number of total number of diagnosed cases, but since they are 
detected early they can be easily treated. With the advent of lower use of postmenopausal 
hormone therapy and more widespread early detection methods such as mammography, 
incidence rates in the U.S., and other western nations, has sharply decreased at the beginning of 
the 2000’s (5, 6).  
Colorectal cancer is the 3rd most and 2nd most commonly diagnosed cancer in males and 
females respectively with 1.2 million new cases and a corresponding 600,000 estimated deaths 
(1, 2). The highest incidence rates tend to be in developed nations such as in Australia, New 
Zealand, Europe and North America (1, 2). Incidence rates have rapidly been increasing in areas 
of the world with historically low rates such as Eastern Asia and Europe due to the 
Westernization of diet and decreased activity (7, 8). The only country with significantly 
decreasing incidence rates in both males and females of colorectal cancer is the United States 
which is indicative of better and more accurate detection and removal of potential carcinogenic 
nodules (8, 9). 
The most commonly diagnosed and leading cause of death globally in males is lung 
cancer (1, 2). It was the 4th commonly diagnosed cancer in females while being the second 
leading cause of death for women (1, 2). Lung cancer results in a total of 13% of all cancer cases 
globally (1, 2). The highest lung cancer incidence rates are in Westernized areas with high 
prevalence of smoking such as in Eastern and Southern Europe, North America, and East Asia 
with sub-Saharan Africa among the lowest due to lower rates and acceptance of smoking 
behaviors (1, 2). The highest incidence rate of lung cancer occurs in Chinese females who have 
rates as high as 21.3 cases per 100,000 (2). High rates in the female Chinese population are 
believed to reflect indoor air pollution from coal-fueled stoves or exposure to other known risk 
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factors such as occupational exposure to asbestos, arsenic, radon, as well as smoking (2, 10-12). 
The worldwide burden of lung cancer primarily results from smoking which accounts for 80% of 
the worldwide cases in males and roughly 50% in females, but death rates in in Western 
countries are decreasing as a result of reduced acceptance and usage of tobacco (2, 13-16). 
When considering liver cancer, 70-85% of all liver cancer cases are Hepatocellular 
Carcinomas (HCCs) (17). Roughly 750,000 new cases of liver cancer occurred in 2008 with a 
corresponding 695,900 cancer related deaths (1, 2). It is the fifth most commonly diagnosed 
cancer in men with a corresponding 2nd most frequently cause of cancer related death worldwide 
(1, 2). It is also the 7th most commonly diagnosed cancer in women and 6th leading cause of 
cancer related death (1, 2). The disparaging fact is that half of all liver cancer cases and deaths 
worldwide occur in China (1). Chronic infection of Hepatitis B virus (HBV) has been identified 
as a primary effector in the development of HCC in populations of Asia or sub-Saharan Africa 
with 8% of the total population in these areas being chronically infected (2). Comparing 
developed to developing nations, HBV infection is responsible for 23% and 60% of total liver 
cancer cases respectively (18). Hepatitis C virus (HCV) infections lead to 33% and 20% of all 
HCC cases in developing and developed nations respectively (18). 
1.2 HEPATOCELLULAR CARCINOMA 
HCC is a disease that affects many populations throughout the world, but has a higher 
incidence in underdeveloped regions due to a lack of infrastructure or resources to manage the 
disease (1, 19). In 2008 there were 748,000 new cases of HCC with corresponding 696,000 
deaths (1, 19). 80% of all cases occurred in underdeveloped regions such as Eastern Asia or 
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Western Africa (1, 19). HCC is also present in developed nations, but at lower rates of incidence 
and mortality, as well as occurring under differing circumstances (2, 20). The difference in the 
observed incidences of HCC between developed and underdeveloped regions primarily stems 
from contrasting environmental and economic factors such as HBV and HCV infections, and 
establishment of effective medical practices for managing the disease (2, 18). Whereas 
underdeveloped nations are susceptible to HCC generation due do chronic HBV infection, 
Westernized areas of the world tend to be burdened by alcohol, obesity and diabetes related liver 
damage and hepatic fibrosis leading to chronic cirrhosis and ultimately HCC (21). The only 
known treatment of HCC, which provides significant health benefit, is liver transplantation, but 
unfortunately there is shortage of organs for transplantation (22, 23). Because of these statistics, 
HCC has become to be the seventh most common cancer in the world, as well as number three in 
cancer related deaths (1, 2, 19). 
1.2.1 Major Global Risk Factors for HCC 
Most of the areas of the world that are underdeveloped have environmental risk factors 
which contribute to the high incidence of HCC. Many of these factors include increased 
incidence of HBV, HCV infections, or the presence of Aflatoxin B1 (AFB1), which are 
responsible for over 80% of all HCCs in these areas (1, 19, 24, 25). Chronic HBV is one of the 
major causes of HCC in underdeveloped areas of the world (18, 25). More than half of all HCC 
cases in the world are a result of HBV infection (18, 25). A study in Taiwan in the 1980s showed 
that men who are chronically infected with HBV are 98.4 times more likely to develop HCC than 
patients without the infection (26, 27). Just as well as HBV infection increases risk for 
development of HCC, HCV leads to chronic liver disease culminating in HCC. In another study, 
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12,008 men in Taiwan were observed over a period of 9.2 years that patients carrying the HCV 
virus had an increased risk of developing HCC about twenty times greater than individuals 
without the infection (28).  
NAFLD is a major precursor to HCC development. It is similar to alcohol induced fatty 
liver damage, but can present in patients who do not readily abuse alcohol. Hepatic steatosis, or 
the accumulation of triglycerides in the hepatocytes, is a hallmark of NAFLD which is also 
strongly associated with obesity and metabolic syndrome (29). After analyzing 11 studies from 
countries such as the United States, Europe and Asia which contained 5,037 overweight and 
6,042 obese individuals compared to normal-weight patients the odds ratios of developing HCC 
was 1.17 and 1.89 respectively indicating that body weight may correlate with an increased risk 
of developing HCC (29) 
  Typically subgroups of patients with NAFLD go on to develop inflammation which 
results in NASH. These events can further progress to fibrosis and cirrhosis that can evolve to 
HCC (30). When considering advanced fibrosis and cirrhosis as a result of NAFLD leading to 
HCC, there seems to be a dichotomy in the molecular pathogenesis of the disease depending on 
the environmental stimuli. Interestingly, patients with NAFLD alone have a lower risk of 
developing advanced cirrhosis or HCC compared to patients with chronic HCV infection with 
rates at 0.6% compared to 17% respectively according to a Japanese study (31). This was 
corroborated in another international study performed in the United Kingdom which showed 
HCC resulting from NAFLD related cirrhosis was 2% compared to chronic HCV induced 
cirrhosis at 7% incidence rates (32). However, liver cancer can also develop in NASH patients 
without advanced fibrosis (33, 34). A Japanese study examined patients who developed HCC as 
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a result of clinically diagnosed NASH and identified that 28% of 19 patients had significantly 
less advanced fibrosis at time of diagnosis of HCC (33). 
NAFLD related HCC is increasing in Westernized nations leading to incidence rates 
between 17-24% (34-36). These statistics may be a result of many things, including the potential 
compounding effect of chronic hepatitis infection on fibrosis leading to HCC development in 
NASH. It has been identified that patients who present chronic HCV infections with NAFLD 
have a 2-3 fold greater risk of developing HCC compared to individuals without NAFLD (37-
39). A study in Japan on incidence rates of patients with NAFLD alone as diagnosed by 
ultrasound, showed an annual rate of 0.043% and a 12 year incidence at 0.5% of HCC indicating 
rarity of NAFLD induced HCC, although patients with advanced fibrosis had a 25-fold increased 
risk of developing HCC (40). Corresponding to this, another study in the United States showed 
patients with NAFLD and advanced cirrhosis having increased incidence rates of HCC from 2% 
over 7 years to 13% over 3 years (41) 
When considering the compounding effect chronic Hepatitis viral infections can have on 
the path to progression of HCC, obesity and other metabolic disorders, such as type 2 Diabetes, 
in conjunction with chronic HBV and HCV infections also increases the risk of developing HCC 
(42-47). A study that followed roughly 5,000 patients for 14 years with type 2 Diabetes and 
obesity which were chronically infected with HBV or HCV, indicated a 100-fold increased risk 
of developing HCC (48). Knowing that Diabetes in NAFLD patients is a prelude to HCC 
development, treatment with insulin-sensitizing drugs has been shown to improve hepatic 
histology including reducing steatosis and inflammation leading to reduced HCC risk (47, 49-
51). 
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1.2.2 HCC in the United States  
Even though developing countries are at significant increased risk of developing HCC as 
a result of chronic HBV infection as opposed to HCV, Westernized nations such as the United 
States are more susceptible to hepatocarcinogenesis by chronic HCV infection rather HBV (24, 
52-54). One of the causes for this is the presence of the HBV vaccination program, which exists 
in the United States to prevent chronic HBV infection. However, within a thirty year time span 
from 1975 to 2005 there was still an increase in incidence of HCC in the United States from 1.6 
cases to 4.9 cases per 100,000 individuals (55). The major risk factor believed to be associated 
with this increased incidence of HCC in the United States is chronic HCV infection (56, 57). 
There are 3 million people in the United States who are chronically infected with HCV, many of 
whom were exposed during the 1960s as a result of poor quality blood transfusions or 
intravenous drug use (58, 59). Individuals carrying HCV develop chronic liver disease with 20 to 
30 percent developing cirrhosis within 20 years of infection setting the stage for the development 
of HCC in 1 to 4 percent of individuals with cirrhotic livers every year (57, 60, 61). It is 
projected that the HCC patient population resulting from chronic HCV infection in the United 
Sates will increase and peak between 2015 and 2020 then gradually fall off (20, 53, 54). 
However, this drop off is expected to be met with an increase of incidence of HCC as a result of 
the growing epidemic of diabetes, obesity, and NAFLD/NASH in the United States which is still 
a reason for concern (62). 
 Cirrhosis as a result of NAFLD is predicted to surpass chronic HCV induced cirrhosis in 
the US within the next 5 years as the burden of HCV decreases and metabolic disorders become 
more prevalent (63). When considering the obesity epidemic, a study conducted on roughly 
900,000 United States citizens over 16 years found that obesity will increase the risk of many 
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cancers, with the greatest effect being on HCC (64). Obesity also plays a role in the development 
of HCC in populations with advanced fibrosis or cirrhosis by about 3 to 11 fold when 
considering undefined cirrhosis or alcoholic induced cirrhosis respectively in a US study done on 
19,271 transplant patients due to cirrhosis (65) 
A population-based study using ultrasonography screens from 12,454 adults who 
participated in the Third National Health and Nutrition Examination Survey conducted in the 
United States from 1988 to 1994 on 20–74 year old individuals suggests that at least 25% of the 
population has NAFLD (66). The study indicated that the rates of hepatic steatosis and NAFLD 
in the United states were 21.4% and 19.0%, respectively, corresponding to an estimated 32.5 
million adults with hepatic steatosis and 28.8 million adults with NAFLD nationwide (66). 
NAFLD incidence rates were highest in Mexican Americans (24.1%) followed by non-Hispanic 
whites (17.8%) and then non-Hispanic blacks (13.5%) with higher incidences in men (20.2%) 
than women (15.8%) (66). This is a large percentage of the United States population which could 
potentially further develop NASH followed by HCC. Studies have shown by using a liver injury 
marker aminotransferase that 6-8% of adults in the United States have NASH (67). 1.5-2% of the 
US population has cirrhosis due to NAFLD, and unfortunately 25% of patients with NASH will 
develop cirrhosis potentially leading to HCC causing them to succumb to liver related disease 
(30, 68, 69).  
1.3 HEPATOCARCINOGENESIS 
HCC development is a process which involves multiple steps during a span of several 
decades (Fig. 1) (70). About 80% of all HCCs are a result of chronic insults to the liver from 
 27 
HBV, HCV, AFB, NAFLD, or NASH resulting in hepatocyte damage, which can trigger 
pathways that induce fibrosis, cirrhosis and eventually lead to development of HCC (24). HBV 
and AFB act synergistically to alter the stability of genomic DNA causing rearrangements, 
breaks, and various mutations such as in the TP53 gene which interrupt the protective nature of 
the p53 protein (71-78). HBV along with HCV may also release viral particles that interrupt 
normal cell stability and metabolism (73, 74, 76). Oxidative stress, as well as nitric-oxide (NO) 
generation resulting from a chronic inflammatory response in the liver upon viral presentation, is 
also one of the underlying causes of mutations which lead to HCC development (52, 79). 
 
 
Figure 1. Pathological progression to HCC. 
1.3.1 Stepwise process to hepatocellular oncogenesis  
Identifying the causative factors of HCC requires deeper insight into the complex 
menagerie of signaling cascades that have an association with the aforementioned chronic 
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hepatitis, alcoholism, diabetes, obesity, metabolic disorders leading to oxidative stress. These 
underlying conditions typically lead to recurring cycles of proliferation, inflammation and 
necrosis that effects every cell in the liver from hepatocytes, endothelial cells, kupffer cells and 
activation of stellate cells which are responsible for the deposition of fibrotic matrix ultimately 
causing cirrhosis (80, 81). Stellate cells are the main source of matrix and collagen in the liver, 
and increased activation of these cells has been shown by oxidative stressors which will lead to 
the synthesis of collagen (82). The deposition of fibrotic matrix represents a wound healing 
response that eventually supports expansion of hepatocytes. Proliferating hepatocytes are easily 
susceptible to oncogenic mutations leading to dysplasia and onset of HCC (83). Oxidative stress 
can lead to hepatocarcinogenesis by several methods such as causing DNA damage and can also 
promote the development of fibrosis and cirrhosis. This has been corroborated in mice which 
overexpress PDGF-C causing the development of fibrosis and ultimately leading to HCC (84). 
Oxidative stress itself has been shown to be related to increased rates of oncogenic mutations 
such as in the p53 gene (85). 
Chronic viral infection can be another mechanism which results in oxidative stress 
leading to HCC. It has been widely accepted that viral induced carcinogenesis is a precursor of 
HCC resulting from host-virus interactions, and are responsible for clearing the viral infection 
leading to enhanced T-cell responses contributing to hepatocyte necrosis, inflammation, and liver 
regeneration under chronic states which result in carcinogenesis (86-88). One potential 
mechanism may stem from endoplasmic reticulum (ER) stress ultimately inducing oxidative 
stress, and leads to activation of proliferation and survival signals thereby resulting in mutations 
via free radical generation culminating in stellate cell activation, which finally leads to matrix 
deposition and potentiation of fibrosis (89-91). HBV infection related carcinogenesis depends on 
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chronic versus acute infection states, of which 10% of individuals infected with HBV have a 
chronic response rather than acute (92). Chronic HBV infection results in continuous replication 
of hepatocytes leading to development and sustaining of oncogenic lesions in DNA and potential 
telomere erosion which all cause genomic instability. The Hepatitis B virus can also insert into 
host DNA and results in host microdeletions which can trigger loss of heterozygosity (LOH) in 
cancer relevant genes such as telomerase reverse transcriptase (TERT), platelet derived growth 
factor receptor β (PDGFRβ), and mitogen activated protein kinase 1 (MAPK1) (93, 94). 
HCV infection has a significant distinction compared to HBV infection in that chronic 
infection occurs in 60-80% of all cases compared to 10% in HBV (88, 95). HCV also more 
frequently leads to cirrhosis compared to HBV at a rate of 5-10% of cases after 10 years of 
chronic infection, which is 10-20 times higher than HBV (88). HCV being a chronic disease 
leads to constant waves of hepatocyte inflammation and necrosis leading to subsequent 
regeneration which tend to make cells more susceptible to developing oncogenic mutations. 
The prototypical hallmarks of HCC generation such as chronic waves of inflammation, 
necrosis of hepatocytes, regeneration and stellate cell activation is not restricted to hepatitis 
infection, as can be observed in chronic alcohol consumption. In the presence of chronic alcohol, 
hepatocytes tend to be more sensitive to TNFα toxic effects which set the groundwork for the 
development of chronic hepatocyte cell death, regeneration, stellate cell activation, cirrhosis and 
ultimately HCC (96). Chronic alcohol intake has been implicated in causing the production of 
factors involved in inflammation and instigating increased levels of endotoxin which in turn 
activate kupffer cells that release chemokines and cytokines such as TNFα, interleukin-1β (IL-
1β), and ΙL6 among others which all play a critical role in hepatocyte survival (97). Alcohol also 
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causes oxidative stress on the liver as shown by clinicopathologic signs of alcoholic hepatitis 
indicated by elevated levels of isoprostane, a marker of lipid peroxidation (96). 
Other environmental factors such as AFB1 have also been shown in the past to contribute 
to hepatocarcinogenesis by frequently causing DNA adducts, specific examples being the p53 
gene as well as other well-known oncogenes such as HRAS (98-103). Counter to chronic 
hepatitis infection or alcohol consumption, there is little evidence that supports exposure to 
AFB1 leading to increased risk of developing fibrosis which will precede cirrhotic development 
and oncogenesis, leading to the justification that AFB1 is a primary mutagen responsible for 
these HCC cases. However, when HBV and AFB1 exposure coexist this leads to a 5-10 fold 
increased risk of developing HCC compared to exposure of only one of these factors (104). 
Mechanistic data in this field falls short, but it is reasonable to believe that the genetic mutations 
resulting from AFB1 exposure will give an oncogenic advantage to cells dividing in response to 
the chronic cell death from HBV infection. 
1.3.2 Biochemical Pathways known to be involved in HCC 
Analysis of oncogenic biochemical pathways in a heterogeneous disease such as HCC 
leads to many challenges in deciding the significance of said pathways, but also indicates the 
importance of developing targeted therapies. For example, p53 is an antiapoptotic regulator, and 
although it is widely accepted that p53 mutations are relevant to hepatocellular oncogenesis, 
whether it plays a role in initiation or promotion of the disease remains less well defined. (105, 
106). Depending on whether HCC development is in the context of HBV, HCV or AFB1, p53 
LOH mutations give mixed results in determining its role as an initiator or an oncogenic 
promoter (98, 99, 107-110). p53 mutations occur at relatively low frequency in HCC, but is 
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frequently induced when underlying conditions exist such as AFB1 exposure is present at about 
50% of all cases for example (100). p53 mutations can occur in HCV induced HCC versus HBV 
induced HCC at 13% and 53% respectively (111).  
Underlying HBV infection can induce a multitude of signaling pathways which are all 
related to oncogenesis. The HBV Protein-X (HBx) can bind and inactivate the tumor suppressor 
p53 by sequestering it in the cytoplasm inhibiting its nuclear functions of promoting cell survival 
(98, 107, 112). HBx can also alter the expression of several important kinases such as Ras, Raf, 
MAPK, ERK, and JNK among others involved in cell survival and proliferation (113-115) (116-
118). Increasing evidence has directly linked HBx protein to hepatocarcinogenesis by showing 
its overexpression can lead to HCC (107). Another specific pathway that HBx has been shown to 
influence is the Wnt/β-catenin signaling pathway (119, 120). Several studies have shown that 
HBx protein is capable of interrupting the E-cadherin-β-catenin interactions at the membrane 
leading to subsequent induction of Wnt related pro-survival and proliferation genes (120-122). 
Other etiologies of HCC, such as HCV and chronic alcohol consumption, result in 
aberrant signaling activation as well such as in the MAPK pathway components ERK, MEK and 
Raf. It can also activate other oncogenic signaling pathways such as the signal transducer and 
activator of transcription 1 (STAT1), which deregulates INFγ activation, thus interfering with 
protective interferon signaling thereby contributing to increased risk of carcinogenesis (123) 
(124, 125). DNA methylation events have also been implicated in HCC development (126-129). 
Specific hypermethylation events in HCC have occurred in genes such as p16(INK4a), E-
Cadherin, COX2 among others, which increase in expression once HCC cells in culture are 
treated with demethylating agents (130-132). These factors are specifically involved in the 
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regulation of cell senescence therefore suggesting epigenetic silencing via methylating events are 
very much apparent in HCC as they are in other cancers. 
Even though diabetes and obesity have shown a significant correlation in NAFLD related 
liver disease, the molecular pathogenesis of the disease progression is not clearly understood. 
There is however a link between PI3K activity being activated by insulin (133, 134). PI3K is a 
signaling pathway which mediates cellular processes such as metabolism, growth, and survival. 
Amplification and enhanced signaling activity in the PI3K pathway are commonly found in 
many cancers which include HCC (135). With this being said, it is possible that increased insulin 
production in a diabetic state may intensify hepatocyte proliferation during steatosis potentially 
leading to the development of HCC. 
Another molecular characteristic of NAFLD induced HCC is that levels of des-γ-
prothrombin tend to be higher compared to α-fetoprotein (136). High α-fetoprotein expression is 
a traditional hallmark of HCC, and this tells us that des-γ-prothrombin might be a great indicator 
to differentiate NAFLD induced HCC for personalized therapy (137, 138). Identifying the 
molecular indicators leading to HCC are the most promising advances in terms of trying to 
develop an effective targeted therapy. For example, genome wide association studies have shown 
that the phospholipase domain containing 3 (PNPLA3) gene may lead to NAFLD induced HCC 
resulting from a genetic mutation in this protein which increases the risk of developing cirrhosis 
thereby increasing the risk of HCC (139).  
NAFLD, obesity and diabetes all share in common a chronic inflammatory state during 
which NF-κB has always been known to be classically activated during chronic inflammatory 
states (140). NF-κB has been shown to have a hand in hepatic steatosis, insulin resistance, 
inflammation, fibrosis and cancer by the interaction of cofactors in the nucleus which induce the 
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production of specific cytokines and factors that play a role in chronic inflammatory responses 
(141-144). A study using mice deficient in NF-κB signaling and fed methionine and choline 
deficient (MCD) diet, which has been classically known to induce NASH, showed that mice 
lacking NF-κB signaling experienced exacerbated inflammation and fibrosis which were caused 
by an upregulation if interlukin-15 (IL-15) expression (145). In an independent study, mice 
deficient in NF-κB signaling specifically in hepatocytes strongly enhances the development of 
diethylnitrosamine (DEN), a known chemical carcinogen used to induce HCC, related liver 
cancer (146). 
Another major molecular mechanism in liver biology is the folate driven one-carbon 
metabolism. One-carbon metabolism is a metabolic network of pathways which exists in 
different compartments within the cell which include the cytoplasm, mitochondria, and nucleus. 
One-carbon metabolism in the cytoplasm is required for the synthesis of purines and thymidylate 
and the remethylation of homocysteine to methionine. One-carbon metabolism in the 
mitochondria is required for the synthesis of formylated methionyl-tRNA; the catabolism of 
choline, purines, and histidine; and the interconversion of serine and glycine (147). One-carbon 
metabolism is regulated by intracellular levels of folate and methionine, and deregulation of this 
pathway has been linked to increased risk of developing cirrhosis leading to HCC as indicated by 
reduced levels of S-adenosylmethionine (SAMe), the key methyl group donor in mammalian 
cells (148). The synthesis and activity of SAMe are regulated by methionine adenosyltransferase 
(MAT) and glycine N-methyltransferase (GNMT), respectively (149-152). Knockout mice of 
either of these enzymes have been shown to be essential in the development of NAFLD related 
HCC (153-155). The MAT protein is encoded by two genes, MAT1A and MAT2A. Interestingly, 
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there is evidence that 60% of patients with cirrhosis have reduced expression of MAT1A, and it is 
also frequently silenced in HCC (156, 157). 
1.4 WNT/β-CATENIN SIGNALING 
The canonical Wnt/β-catenin signaling pathway is an evolutionary conserved signaling 
pathway with many important functions during development and in adult homeostasis. Wnts are 
secreted cysteine rich glycoproteins from epithelial, mural, or endothelial cells, which bind to 
receptor Frizzled (Fzd) and co-receptor low-density lipoprotein receptor related protein (LRP) 5 
or 6 (158). This initiates a cascade of events beginning with the activation of an intracellular 
protein called Disheveled (Dvl) which subsequently causes inactivation of a degradation 
complex composed of glycogen synthase kinase-3β (GSK-3β), adenomatous polyposis coli 
(APC), and Axin (159-166). GSK-3β has been shown to be the gatekeeper of Wnt/β-catenin 
signaling, and once active it phosphorylates β-catenin at specific sites at the amino-terminus, 
targeting it for proteasomal degradation (161-163). However, in the presence of Wnt signal, the 
degradation complex is inactivated, β-catenin builds up in the cytoplasm and promptly 
translocates into the nucleus where it can interact with histone acetyl transferases such as cAMP 
response element-binding protein (CREB)-binding protein (CBP) and p300, transcription factors 
belonging to T-cell factor/lymphoid enhancing factor (TCF/LEF) family or co-factors such as B-
cell CLL/lymphoma 9 (BCL-9) protein which in turn regulate the transcription of specific target 
genes (Fig. 2) (167-170). Several different factors have been shown to be subject to β-catenin 
regulation such as Cyclin D1, c-myc, glutamine synthetase (GS), and others that play a role in 
cell cycle, migration, survival and metabolism (171-173). In absence of Wnt signal, β-catenin is 
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phosphorylated at specific serine and threonine residues in exon-3, making it a target of 
ubiquitin-proteasome degradation. 
 
 
Figure 2. Schematic representation of Wnt/β-catenin signaling pathway. 
1.4.1 Wnt/β-catenin signaling in HCC 
Understanding the molecular role Wnt/β-catenin signaling plays in HCC development is 
critical in the development of effective therapies against aberrant Wnt signaling. Because of the 
role β-catenin has in regulating cellular proliferation, it is considered an oncogene in specific 
cancers such as colorectal and HCC (163, 171, 173-175). Some studies indicate β-catenin 
overexpression and mutations are related to early onset HCCs, as well as its involvement in 
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disease progression (176, 177). With this being said, β-catenin activation seems to be playing an 
ambiguous role between disease initiation and disease progression, which is a field in need of 
deeper characterization. However, in terms of underlying HBV and HCV infection, 
overexpression and mutational changes in β-catenin occur more frequently in HCV related HCCs 
than HBV related HCCs (178-180). It has also been suggested that β-catenin mutations are 
typical in HCCs that are not characterized by genomic instability because studies have shown 
that HCCs possessing high rates of LOH exhibit low levels of β-catenin activating mutations 
(181, 182). This indicates the potential for deregulated β-catenin signaling to be a specific 
causative factor in the development of HCCs. 
β-catenin mutations and increased nuclear localization have been detected in human 
HCCs. In primary HCC, mutations in the CTNNB1 gene leading to aberrant activation occur in 
about 10-30% of cases, while total upregeulated Wnt signaling activation can occur in about 40-
60% of all HCC cases (163, 175, 180, 183-190). Mutations in the CTNNB1 gene which render β-
catenin constitutively active occur due to either a mutation causing a truncation at the amino-
terminus, or point mutations of critical serine/threonine residues, ultimately resulting in 
hypophosphorylated β-catenin (163, 175, 189, 190). The signaling pathway is highly regulated, 
but a mutation, alteration, or a truncation in specific parts of the gene lead to non-degradable β-
catenin protein causing its constitutive activation, resulting in over-expression of downstream 
targets (163, 171-173, 175). Under specific conditions it is possible to selectively activate the 
Wnt/β-catenin signaling pathway such as in the case of c-myc and E2f1 transgenic mice (191). 
These transgenic mice have been shown to resemble human HCC, and frequently result in 
genetic mutations in β-catenin (191).  
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We have shown aberrant intratumoral β-catenin stabilization in 33% of HCC cases with 
9% showing predominant nuclear with some cytoplasmic (N/C) localization and 24% displaying 
predominant cytoplasmic with occasional nuclear (C/N) localization (192).  Identification of this 
aberrant β-catenin localization correlated with various tumor attributes such as reduced fibrosis, 
increased GS, increased inflammation and increased tumor cellular proliferation, making it an 
attractive target for treatment in a specific group of HCC patients. 
1.5 CURRENT THERAPEUTIC STRATEGIES FOR HCC 
Current methods of treating primary HCC are slim with the majority of cases using a 
multi-tyrosine kinase inhibitor known as Sorafenib to combat the disease. Surgical resection 
including partial hepatectomy tends to be the most common method of treatment, and also 
potentially leads to disease regression with improved five years of disease-free survival (22). 
Orthotopic liver transplantation is another treatment modality when applicable. The only caveat 
to this procedure is the apparent lack of donor organs. As discussed in previous sections, HCC is 
a highly heterogeneous disease resulting from a multitude of aberrant signaling activations in 
part from etiological differences of underlying diseases. There are significant differences in 
progression to HCC between, for example, chronic HBV infection and NAFLD related HCCs, 
but the underlying molecular mechanisms leading to oncogenesis in each case do share some 
commonalities allowing for targeted therapies to be beneficial for all. 
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1.5.1 Sorafenib and TACE in HCC 
Physicians have taken advantage of the fact that HCC is a highly vascularized tumor 
deriving its blood supply from chiefly the hepatic artery. Since liver has a dual blood supply with 
most of its supply from portal vein, a technique was developed which utilizes impeding the flow 
of the hepatic artery to the tumor called Trans-arterial Chemoembolization (TACE) (193). TACE 
delivers chemotherapy locally to the site of the primary HCC, and more frequently includes the 
use of beads laced with Doxorubicin to patients who have an unresectable HCC and patients 
ineligible for transplantation. TACE has been an effective means to control HCC. However, 
since TACE causes hypoxia in the tumor, these hypoxic events lead to production of angiogenic 
signals such as VEGF-A. These events occur temporarily after TACE as early as a few hours 
after intervention, which can ultimately reduce TACE’s efficacy (194-197). Combined with the 
fact that HCCs show increased expression of VEGFRs and PDGFRs, which are involved in 
angiogenic signaling, clinicians suggest that anti-angiogenic intervention during TACE may be 
beneficial to its effectiveness (198-200). 
Sorafenib is a multikinase inhibitor and targets these specific receptors, and has shown to 
be modestly effective in terms of increasing the survival of patients with HCC (201, 202). 
However, a Phase III clinical trial which included the use of traditional TACE followed by 
administration of Sorafenib 1-3 months following TACE failed to show any survival benefit 
(203).  Only when Sorafenib was combined with TACE administered Doxorubicin-eluting beads 
(DEBs) in a Phase II clinical trial, it showed the first evidence that combined therapy is 
beneficial in HCC patients with unresectable cancer leading to a 95% disease control rate and 
roughly 60% of tumors responding to treatment (204). In fact combinatorial therapy of Sorafenib 
and TACE has been shown to increase tumor shrinkage from 29% to 62% in patients treated with 
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a placebo or Sorafenib respectively (205). Since Sorafenib has minimal efficacy where it only 
has a 3 month added median benefit to survival, more effective molecular therapeutic strategies 
are needed (201). Unfortunately in cancer, inhibition of one signaling pathway can potentially 
lead to feedback activation of another oncogenic pathway, which is why multidirectional 
therapeutics is potentially the best course of treatment (206). 
Single agent therapies have modest disease control, but it is widely accepted that 
combination therapeutics may provide the best course of treatment. Combination therapies using 
TACE and anti-angiogenic therapies are becoming increasingly common in clinical trials. An 
example is the use of Axitinib, a multi-Tyrosine Kinase Inhibitor (TKI) of VEGFR1, VEGFR2, 
VEGFR3, PDGFRs, and c-kit in unresectable HCC (NCT01352728) (207). Sorafenib currently 
has been combined with a multitude of therapeutic agents in order to identify the most effective 
combinatorial avenue such as Erlotinib, an EGFR inhibitor, which are in different phases of 
clinical trials (NCT00901901) (205, 207-210).  
1.5.2 Current clinical trial developments 
Granted that cirrhosis is a clinicopathologic precursor to HCC, this condition makes 
following HCC clinically difficult due to biological complications. A preliminary development 
in following HCC patients has shown that analysis of systemic alpha-feto protein (AFP), a serum 
glycoprotein secreted in approximately 70% of HCCs, following therapeutic intervention showed 
a 30% reduction in levels in serum and correlated with increased survival (211). Not only are 
better methods of detecting and mediating HCC, better methods of therapeutic intervention, 
many TKIs, are being developed during clinical trials for HCC intervention. Sunitinib is a multi-
TKI receptor inhibitor that targets VEGFRs, PDGFRs and c-kit in Phase III of clinical trials 
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(212). Brivanib is a dual VEGFR and FGFR inhibitor which has moved into Phase III clinical 
trials as well for unresectable, advanced or metastatic HCC, and has shown to have a decent 
effect on increasing overall survival in HCC patients by about 10 months and the median 
progression free survival in patients was about 3 months (213, 214). Brivanib is currently 
undergoing deeper investigation into therapeutics compared to Sorafenib in an ongoing current 
clinical trial directly comparing the two systemic therapies (BRISK-FL NCT00858871) as well 
as being used in another clinical trial in patients who have failed with Sorafenib treatment 
(BRISK-PS NCT00825955) (207).  
Anti-angiogenic therapeutics have also been explored as a possible treatment avenue for 
HCC patients. Bevacizumab, a monoclonal antibody targeting VEGF-A, has been used in Phase 
II clinical trials for HCC showing a response in 13% of cases, however complications arise using 
this type of treatment in patients with severe cirrhosis as they experience increased risk of 
hemorrhage leading to grade 3 toxicities (215). Ramucirumab is another monoclonal antibody 
however it targets VEGFR2, the active receptor for VEGF-A, which has been applied in HCC 
patients. In a Phase II clinical trial, Ramucirumab has shown a response in 43% of patients in the 
trial, as well as an increased progression free survival rate at 4.3 months with a median overall 
survival of 12 months (216). Currently a Phase III clinical trial using Ramucirumab is planned in 
patients who have already undergone Sorafenib therapy (NCT01140347) (207). 
Targeting EGFR has been postulated to be an avenue to pursue in HCC therapeutics. 
However clinical trials using approved EGFR TKIs Gefitinib, Erlotinib, and Lapatinib  in Phase 
II clinical trials only showed response rates ranging from 0%-9% with progression free survivals 
also minimally ranging from roughly 2-3 months (217-220). Another EGFR inhibitor, 
Cetuximab, showed no disease response as well as progression free survival at less than 2 
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months in Phase II clinical trials indicating that if an EGFR inhibitor were to be pursued for 
HCC it may be wise to validate the whether or not EGFR is playing a critical role in the disease 
prior to administration of an EGFR TKI (221). Combinatorial therapy using Becacizumab and 
Erlotinib, which will target both VEGF-A and EGF signaling, have been investigated in HCC 
with differing results. One study has showed the combination results in 25% tumor response with 
average progression free survival at 9 months and overall survival benefit at roughly 16 months, 
but another study conducted in Asia with a significantly lower response, which may result from 
molecular differences of underlying chronic conditions leading to HCC development (222, 223). 
c-Met is a surface receptor in hepatocytes which, when in the presence of hepatocyte 
growth factor (HGF), can activate intracellular kinase pathways to induce cellular proliferation. 
It is upregulated in roughly 20% of human HCCs (224, 225). ARQ197 is a TKI inhibitor of c-
Met and has undergone Phase I clinical trials to show that inhibition of c-Met signaling results in 
HCC disease stabilization and some patients even continue to have disease stabilization after 4 
months of therapy with minor toxicity and having a wide range of time to progression in disease 
ranging from 3 to 42 weeks (226). There is a current Phase II clinical trial ongoing comparing 
ARQ197 to placebo in patients with unresectable HCC who have previously failed other avenues 
of treatment (NCT00988741) (207). Another TKI inhibitor of c-Met which also targets VEGFR2 
called Foretinib is undergoing Phase I safety trials for patients who have failed a first line 
method of treatment (NCT00920192) (207). 
The PI3K/Akt/mTOR signaling cascade has been known to be oncogenically activated in 
multiple cancer types, and components of this pathway have been shown to be aberrantly 
activated in 40-50% of all HCCs (227, 228). An mTOR inhibitor, Everolimus, has undergone 
Phase I clinical trials in 28 patients with advanced HCC which have undergone previous 
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treatments. In these cases, disease control was 44% and median survival was 8.4 months after 
therapeutic intervention (229). Currently, Everolimus is undergoing Phase III clinical trials in 
individuals who have failed Sorafenib therapy (NCT01035229) (207). An additional mTOR 
inhibitor, Temsirolimus, is currently undergoing Phase II clinical trials in patients with 
histologically positive HCC (NCT01251458) (207). 
Downstream signaling cascades resulting from aberrant RTK activity is critical to 
developing oncogenesis, and one significant pathway which is involved in a multitude of cancers 
is the Ras/Raf/MAPK pathway. It is aberrantly active in 50 – 100% of all HCCs, and when HCC 
cells in culture are treated with MEK1/2 specific inhibitors U0126 and PD98059 led to 
significant cell growth inhibition and apoptosis (230). A MEK1/2 inhibitor, Selumatinib, has 
undergone Phase II clinical trials where there was no response to the therapy as well as a 
depressing progression free survival of only 1.4 months indicating again that even though a 
critical RTK pathway may be targeted, the disease may progress to a point where it can rely on 
alternate pathways for survival (231). 
Epigenetics studies the modification of gene expression occurring without mutagenic 
alteration in the nucleotide sequence. The two key epigenetic mechanisms are hypermethylation 
and histone acetylation (232). Specific underlying conditions such as chronic HBV infection has 
been associated with increase rates of hypermethylation in CpG islands in dysplastic, early onset 
HCCs leading to the realization that epigenetic changes are part of the oncogenic process in HCC 
development (233). Histone deacetylases (HDACs) are responsible for controlling the coiling 
and uncoiling of DNA via acetylation of the histones which condense the DNA. It is possible to 
control both methylation and acetylation events as shown in numerous preclinical models where 
use of HDAC inhibitors can lead to HCC cell death as a result of reactivation of tumor 
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suppressor genes (234-236). A Phase II clinical trial has been completed using the HDAC 
inhibitor Belinostat in patients with advanced HCC who have had another form of therapeutic 
intervention. Disease stabilization occurred in roughly 48% of patients in the trial, with a disease 
free progression of roughly 3 months while increase overall survival of about 7 months without 
major grade toxicities (NCT00321594) (237).  
1.5.3 Preclinical Developments 
There are several additional TKIs in preclinical development that target VEGFRs, 
PDGFRs, and FGFRs such as SU6668/TSU-68 and Dovitinib, which have been shown to be 
effective in reducing angiogenesis as well as disease burden in preclinical tumor models (238-
241). Dovitinib is currently being evaluated in comparison to Sorafenib therapy in phase II 
clinical trials (NCT01232296) (207). However, without molecular classification and 
identification of driver oncogenes in HCC effective therapies for controlling HCC are still 
beyond our reach (242). 
Current therapeutic strategies are beginning to take advantage of specific pathways which 
are upregulated in HCC, such as the Wnt pathway, or pathways which lead to a biological event 
which HCC has become addicted to, such as angiogenesis. A current study done in vitro and in 
vivo showed that a combination therapy of interferon-α and 5-fluorouracil inhibited HCC tumor 
angiogenesis by reducing VEGF and angiopoietin 1 and 2 (Ang1 and Ang2) levels (243). β-
catenin has been targeted by various groups in several different methods in vitro as well as in 
vivo (244-246). One study examined the role of cyclooxygenase-2 (COX-2) in inhibiting β-
catenin activity in HCC cell lines (244). It was shown that in the presence of Celecoxib, COX-2 
inhibitor, and R-Etodolac, a nonsteroidal anti-inflammatory drug, that Wnt signaling in HCC cell 
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lines was significantly diminished as well as the production of downstream targets of β-catenin 
(244). Another independent group has shown the development of a novel, small molecule, ICG-
001, which was shown to significantly reduce β-catenin activity in colon cancer cell lines at 5 
µM doses (245). Currently, a second generation of ICG-001, PRI-724, is undergoing multiple 
Phase I and Phase II clinical trials for pancreatic adenocarcinoma, solid tumors, and for myeloid 
malignancies respectively (NCT01764477) (NCT01302405) (NCT01606579). 
These studies elucidate and suggest the potential to utilize β-catenin as a potential 
therapeutic target in HCC. Considering that β-catenin highly regulates many factors which 
control angiogenesis, one might think that a therapy which targets β-catenin in HCC will not 
only slow down the proliferative potential of the tumor cells, but also inhibit the growth of new 
vasculature into the tumor, which will in turn choke the growth of HCC. All of these factors 
point to the strong idea that a therapy which will target β-catenin will also target angiogenesis in 
a growing HCC mass providing a multiple step therapy which in the end will be more effective 
than targeting a single therapeutic aspect. 
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Figure 3. Outline of molecules and respective targeted sites of action currently under investigation 
for therapeutic benefit in clinical and pre-clinical models. 
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1.6 CURRENT CONTRIBUTIONS OF BETA-CATENIN TARGETED 
THERAPEUTICS IN HCC 
With the current global prevalence and future trends in HCC incidence, a new modality 
of therapy is required to combat the disease. Knowing the importance and potential implications 
β-catenin directed therapeutics may have on HCC we were inspired to try multiple avenues in 
targeting β-catenin and aberrant Wnt signaling in HCC. Our lab has already shown that targeting 
β-catenin via silencing RNA (siRNA) leads to significant cell growth inhibition as well as 
apoptosis in HCC cells in vitro {Zeng, 2007 #131}. We now believe that targeting active Wnt 
signaling in HCC specifically is possible and will be a useful targeted therapy for a subset of 
tumors (247). Considering how there is no Wnt/β-catenin targeted therapeutic approved for use 
in the clinic, or even undergoing clinical trials for HCC, we believe there is a significant need to 
develop a therapy for the 40-60% of patients with aberrant HCC. 
 Chapter one will discuss the development of a SM inhibitor, which much like ICG-001, 
inhibits activated Wnt/β-catenin signaling in HCC cells as well as in zebrafish. This SM, 
PMED-1, inhibits β-catenin/CBP interaction, causing a decrease in β-catenin driven downstream 
targets leading to a significant inhibition of HCC cell growth and survival in vitro. The second 
chapter will discuss the synthesis, development, and characterization of a novel type of antisense 
nucleic acid called the peptide nucleic acids (PNAs). PNAs are unique in that they can enter into 
cells passively and affect target gene expression directly with little to no off target toxicity in 
vitro (248). We utilize PNA directed again β-catenin to diminish its expression in HCC cells, and 
much like the use of siRNA, HCC cells succumb to β-catenin knockdown secondary to 
decreased expression of its targets that in turn led to reduced survival and proliferation. Finally, 
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chapter three discusses another antisense technology for targeting β-catenin in vivo in HCC. 
Locked Nucleic Acids (LNAs) are a timely and novel means that very effectively affect gene 
expression and have the advantage of being stable and specific and currently in various phases of 
clinical trials for genes such as miRNA-122. We, for the first time show that an LNA-directed 
against β-catenin dramatically decreased tumor burden in mice in a model where HCC occurred 
secondary to β-catenin gene mutations. Altogether, these data demonstrate the significant 
potential and need for β-catenin directed therapeutics for patients with activated Wnt signaling. 
Development of agents targeting β-catenin may pave the way towards personalized therapies in 
HCC patients who specifically have aberrantly active Wnt signaling. 
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2.0  IDENTIFICATION AND CHARACTERIZATION OF A NOVEL SMALL 
MOLECULE INHIBITOR OF BETA-CATENIN SIGNALING IN HEPATOCELLULAR 
CANCER CELLS 
The following body of work focuses on identifying a novel small molecule inhibitor that 
resembles ICG-001, a previously described SM inhibitor of Wnt signaling, to target β-catenin in 
HCC cells. By applying a cost-effective, efficacious, and simplistic method of SM identification 
rather than traditional high-throughput screening we show that based solely on the structure of 
ICG-001, we were able to identify two SMs that significantly inhibit β-catenin activity. One of 
these compounds labeled hereon as PMED-1 showed no toxicity to primary human hepatocytes 
and lacked any off target effects. We further show that PMED-1, like ICG-001, inhibits β-
catenin signaling by not altering β-catenin expression but rather by impeding β-catenin-CBP 
interactions, which in turn affects tumor cell proliferation and viability in multiple HCC cell 
lines. Thus our findings highlight the relevance of similarity searches in streamlining drug 
discovery and at the same time report discovery of a prospective SM that may be effective 
against β-catenin in HCC cells. 
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2.1 IDENTIFICATION OF SMALL MOLECULES TARGETING WNT/BETA-
CATENIN SIGNALING 
ICG-001 is a SM, which significantly reduces β-catenin activity in colon cancer cell lines 
at 5 µM concentration (245). ICG-001 and its next generation derivative PRI-724, which is in 
phase I clinical trials, inhibits β-catenin signaling by blocking β-catenin-CBP interactions (249). 
Using an agent similar to ICG-001 will be of high relevance in 30% of HCCs where point 
mutations in exon-3 of the CTNNB1 gene affect key serine/threonine residues rendering β-
catenin stable and constitutively active (163, 175, 189, 190). In this subset, mutant β-catenin 
targeting in the nuclei to impair its interactions with CBP to impair expression of several target 
genes in the tumor will be of high therapeutic relevance.  
2.1.1 Structural similarity search reveals ICG-001 analogs 
Recognition of small molecules by proteins is largely mediated by molecular surface 
complementarities. Structure-based drug design approaches use this as the fundamental guiding 
principle, i.e., closely related molecules will elicit similar activity in a biological assay (250, 
251). Our starting point was to identify compounds similar to ICG-001 that would serve as 
structural analogues by screening the drug-like subset of the ZINC 8.0 database (approximately 
3.5 million compounds) (Fig. 4A) (252). This search yielded a large number of around 13,400 
compounds, which were sorted by similarity score. We retained 24 compounds that showed a 
similarity score of almost 70%. 
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2.1.2 In silico toxicity prediction reveals promising small molecules 
Since most failures in clinical trials result from issues related to drug pharmacodynamics 
and pharmacokinetics, all state-of-the-art drug discovery strategies and programs now 
incorporate the evaluation of absorption, distribution, metabolism and excretion (ADME) and 
toxicological (Tox) properties early in the discovery process to mitigate this risk. Next, we 
applied an in silico ADME/Tox filtering to prioritize the compounds for purchase and further 
characterization. Twenty out of the 24 compounds passed all the ADME/Tox filters and the 
structure of the top 2 molecules labeled as PMED-1 and PMED-2 along with the structure of 
ICG-001 are shown (Fig. 4B-D). 
 
 
Figure 4. Computational approach and structures of investigated small molecules. (A) Using the 
ZINC 3.0 database we were able to identify 13,399 small molecules structurally similar to ICG-001 available for 
purchase. A similarity score of 70% restricted the hits to 24 molecules, of which 20 passed in silico ADME/Toxicity 
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filtering, which were subsequently purchased for biological testing. (B) Chemical structure of ICG-001. (C) 
Chemical structure of PMED-1. (D) Chemical structure of PMED-2. 
2.2 BIOLOGICAL VALIDATION OF LEAD SMALL MOLECULES 
To generate a biologically active complex that can regulate expression of downstream 
target genes such as Cyclin-D1, c-myc, GS, and VEGF-A, (171-173, 253) β-catenin not only 
must interact with transcription factors like TCF4, but recruits other essential transcriptional 
regulators such as histone acetyl transferases, one specifically being CBP. β-catenin signaling is 
active in a significant subset of HCC patients due to multitude of causes various proof of concept 
studies have shown therapeutic efficacy of inhibiting β-catenin as a treatment strategy for this 
tumor type, both in vitro and in vivo (244, 246, 248, 254). However, developing an effective 
small molecule from in silico to bench to bedside all has its challenges due to complexity of 
biological systems. In the current study, we took an in silico approach to identify PMED-1 to 
then validate in HCC cells and eventually tested its efficacy in vivo in zebrafish to discover a 
novel SM that effectively inhibits Wnt/β-catenin. 
2.2.1 Identifying small molecules capable of inhibiting Wnt/β-catenin signaling in vitro 
In order to characterize the effectiveness of the top two SMs in inhibiting β-catenin/TCF 
activity, we utilized human hepatoblastoma cell line (HepG2), which harbors constitutively 
active β-catenin due to monoallelic deletion in exon-3 of CTNNB1, by TOPFlash luciferase 
reporter assay (255). HepG2 cells were treated with 2% DMSO, 200 µM PMED-1, or 200 µM 
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PMED-2 for 24 hours. A 50% or 80% decrease in TOPFlash reporter activity was observed 
following PMED-1 or PMED-2 treatment respectively (Fig. 5A). When primary hepatocytes 
were treated with 200 µM of either PMED-1 or PMED-2 in comparison to 2% DMSO control 
for 18 hours, there was no change observed in cell viability as assayed by MTT assay (Fig. 5B). 
However at 48 hours, while PMED-1 showed no toxicity, PMED-2 led to a significant decrease 
in hepatocyte viability by MTT assay (Fig. 5B). 
2.2.2 Toxicity studies reveal PMED-1 to be top candidate 
Since PMED-1 was non-toxic to primary human hepatocytes, we further assessed its 
impact on HepG2 cells. Treatment of these cells with 200 µM PMED-1 led to a significant cell 
death as observed by live cell imaging showing normally spread viable hepatocytes in control 
versus clumped, rounded cells in PMED-1 treated cultures (Fig. 5C). This was further validated 
at a lower dose when 100 µM PMED-1 treatment of HepG2 cells for 24 or 48 hours led to 
around 30-35% reduction of viability by MTT assay (Fig. 5D). These results indicate that 
although both PMED-1 and PMED-2 decrease β-catenin activity, only PMED-1 is selectively 
toxic to HepG2 cells and not primary hepatocytes. 
2.3 INVESTIGATING TIME AND DOSE DEPENDENCY OF PMED-1 
Drug stability and activity is full of complex intricacies which make identifying the true 
effectiveness of a SM challenging. In order to tease out the possible effectiveness of a SM, dose 
dependency and time course studies are the traditional way to figure out how long a molecule 
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will retain its activity, as well as the optimal dose. The ideal goal in this aspect is to reach what is 
now known as the half maximal inhibitory concentration (IC50). The IC50 will give an idea of 
what concentration and how long the duration of treatment will be resulting in 50% reduction in 
a specific characteristic of interest such as activity or viability.  
 
 
Figure 5. Effect of PMED-1 and PMED-2 on HepG2 cell line and normal human hepatocytes. (A) HepG2 cells 
treated with 200 µM PMED-1 or 200 µM PMED-2 for 24 hours show significant decrease in TOPFlash luciferase 
reporter activity as compared to 2% DMSO treatment. (B) Primary hepatocytes treated with 2% DMSO, 200 µM 
PMED-1 or 200 µM PMED-2 for 18 or 48 hours show a significant decrease in viability by MTT assay only after 
PMED-2 treatment for 48 hours. (C) HepG2 cells treated with 200 µM PMED-1 for 24 hours monitored by live cell 
imaging using Nikon Eclipse Ti live cell imager shows notable morphological changes reminiscent of cell death as 
early as 3 hours after treatment when compared to the 2% DMSO-treated controls. (D) HepG2 cells treated for 24 or 
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48 hours with 100 µM PMED-1 leads to a significant decrease in cell viability as assessed by MTT assay as 
compared to 1% DMSO control. 
2.3.1 Wnt/β-catenin activity assay studies PMED-1 efficacy 
We performed dose response of PMED-1 using the TOPFlash reporter activity in HepG2 
cells. HepG2 cells were treated with PMED-1 for 24 hours at a concentration ranging from 200 
µM to 500 nM. A significant decrease in TOPFlash reporter activity was only observed at a 
concentration of 25 µM or higher (data not shown). Intriguingly when HepG2 cells were treated 
for 24 and 48 hours, TOPFlash reporter activity was decreased significantly at both times, 
although the extent of decrease at 48 hours was less than 24 hours, suggesting metabolic 
inactivation of the SM (Fig. 6A). Thymidine incorporation, which is a measure of DNA 
synthesis, however showed significant decrease at both 24 and 72 hours after PMED-1 treatment 
when compared to DMSO control (Fig. 6B). This was also verified by immunofluorescence for 
Ki-67, an S-phase marker of cell cycle, which showed a notable decrease after PMED-1 as 
compared to DMSO treatment of HepG2 cells for 24 hours (Fig. 6C). 
2.3.2 Inhibiting cell cycle progression and growth supports activity assay 
Since a significant decrease in TOPFlash reporter activity in HepG2 cells was observed at 
24 hours after PMED-1 treatment at 25 µM, we next examined the status of β-catenin and 
protein expression of some of its downstream targets. As seen in Figure 6D, while no change in 
total β-catenin was evident, a notable decrease in GS, Cyclin-D1, c-myc, and Regucalcin protein 
levels was evident. Thus treatment with PMED-1 impedes β-catenin signaling in HepG2 cells. 
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Figure 6. PMED-1 targets β-catenin signaling to affect cell proliferation in HepG2 cells. (A) HepG2 cells 
treated with 100 µM or 25 µM for 24 hours with PMED-1 showed a more significant decrease in TOPFlash reporter 
activity assay than at 48 hours. (B) DNA synthesis in HepG2 cells measured by thymidine incorporation shows a 
significant decrease in response to 24 or 72 hour treatment with 100 µM or 25 µM of PMED-1 when compared to 
0.2% DMSO. (C) Decrease in Ki-67 positive cells (red) was noticed after treatment of HepG2 cells with 25 µM 
PMED-1 as compared to 0.2% DMSO. (D) Western blots with whole cell lysates from HepG2’s treated with 25 µM 
PMED-1 show a notable decrease in β-catenin targets without affecting its protein expression when compared to the 
DMSO control. β-actin verified comparable protein loading. 
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2.4 HCC CELL LINE SPECIFICITY OF PMED-1 EXAMINED 
Many times when an experimental SM is developed, its activity and metabolism differ 
when used in different cell types or cell lines. This is possible due to the fact that in culture, 
mutations may frequently occur during passaging of the cell line leading to resistances or 
susceptibilities to specified treatments. Cell line/type specificity can also occur especially in 
cases where specific cell lines don’t even express proteins which a SM therapy is targeted. 
2.4.1 Multiple HCC cell lines are susceptible to PMED-1 via TOPFlash assay  
In order to further substantiate the anti-β-catenin effect of PMED-1, we treated various 
HCC cell lines that express endogenous wild-type (WT) β-catenin (Snu-449, Huh7, Hep3B), 
endogenous mutated β-catenin (Snu-398) or a stable cell line expressing either WT-β-catenin 
(Hep3B-WT) or constitutively active mutated β-catenin (Hep3B-S33Y) (248, 256, 257). Twenty-
four hour treatment of all cell lines with 25 µM PMED-1 led to a significant decrease in 
TOPFlash reporter activity ranging from 15% to 50% as compared to DMSO treatment (Fig. 
7A). PMED-1 treatment also led to a significant decrease in cell viability in various HCC cell 
lines at the corresponding times when compared to the DMSO controls (Fig. 7B). As shown in a 
representative analysis, PMED-1 treatment also led to a significant decrease in thymidine 
incorporation in Snu-398 cells at both 24 and 72 hours (Fig. 7C). 
 57 
2.4.2 PMED-1 causes consistent inhibition of Wnt target gene expression in multiple HCC 
cell lines  
To further demonstrate the impact of PMED-1 on β-catenin signaling in these HCC cell 
lines, we analyzed whole cell lysates for the protein expression of β-catenin and some of its 
known targets. A notable decrease in GS, Cyclin-D1, and VEGF-A was observed after 24 hours 
of PMED-1 treatment on various HCC cells without any impact on total β-catenin levels (Fig. 
7D). Taken together, this data supports that PMED-1 is indeed effective in targeting β-catenin 
activity in multiple HCC cells and thus has significant biological implications. 
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Figure 7. PMED-1 targets β-catenin effectively in multiple HCC cell lines. (A) TOPFlash luciferase assay 
conducted in Snu-398, Snu-449, Hep3B-WT, Hep3B-S33Y, and Huh7 HCC cells after 25 µM PMED-1 treatment 
for 24 hours shows a significant and consistent decrease although the extent of decrease varied among various cell 
lines. (B) MTT assay shows a significant decrease in viability of Snu-398, Hep3B, and Huh7 HCC cells after 24 
hour of 25 µM PMED-1 as compared to 1% DMSO. (C) DNA synthesis measured by thymidine incorporation is 
significantly reduced in Snu-398 HCC cells treated for 24 or 72 hours with 25 µM PMED-1 as compared to 0.05% 
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DMSO. (D) Western blots using whole cell lysates from Huh7, Snu-449, Snu-398, Hep3B-WT, and Hep3B S33Y 
HCC cells treated with 25 µM PMED-1 show notable decreases in β-catenin downstream targets without affecting 
total β-catenin levels when compared to 0.05% DMSO control. β-actin verified comparable protein loading. 
2.5 ACTIVITY SPECIFICITY OF PMED-1 MIMICS ICG-001 
Identifying an active SM which inhibits Wnt signaling that is structurally similar to ICG-
001, a known β-catenin inhibitor, through in silico techniques is hypothetical at this point in 
time. In order to validate the hypothesis, studying the specific activity of PMED-1 versus ICG-
001 is required. Also, we wanted to make sure that PMED-1 was not having any adverse off 
target effects against any other critical signaling pathway in the cell which could have been 
giving us false positive results. Target specificity is of utmost importance when developing a 
novel therapy from bench top to bedside in order to reduce any toxicity a patient would 
potentially experience. 
2.5.1 Co-immunoprecipitation of CBP/β-catenin shows PMED-1 activity 
In order to address the molecular basis of β-catenin inhibition by PMED-1, we verified 
the mechanism of β-catenin inhibition brought about by ICG-001. In agreement with the 
previously published studies, treatment of HepG2 and Snu-398 cells for 24 hours with ICG-001 
led to a notable decrease in CBP-β-catenin association as demonstrated by immunoprecipitation 
studies (Fig. 8A). Since PMED-1 was identified by structure-function based computational 
search, an evident decrease in the association of these two proteins when compared to no 
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treatment or DMSO control validated our computational search (Fig. 8A). This data suggests 
that our computational strategy successfully yielded a SM having structure-function similarity to 
ICG-001. 
2.5.2 PMED-1 does not show off target kinase inhibition 
To further verify if PMED-1 could potentially affect additional kinases that may be 
resulting in some of the observed biological effects, we compared its efficacy to a multi-kinase 
inhibitor H89 in inhibiting key kinases including AKT, PKD, CAK, Plk1 and Plk2. While in 
response to H89, a dose-dependent inhibition of AKT (Fig. 8B), CAK (Fig. 8D), PKD (Fig. 8F), 
Plk1 (Fig. 8H) and Plk2 (Fig. 8J) was observed, no inhibition of these kinases was evident after 
PMED-1 treatment (Fig. 8C, 8E, 8G, 8I and 8K). Intriguingly low doses of PMED-1 showed 
60% (-2.5 to -1.0 log µM representing 0.003 µM to 0.09 µM) showed an inverse decrease in 
Plk1 kinase, however at higher dose, this activity was lost (Fig. 8I). It should be noted that 25 
µM equivalent of PMED-1, which significantly decreased β-catenin-TCF activity in HCC cells 
showed no inhibition of any of the 5 kinases tested at that concentration, which equates to 1.39 
log µM. This analysis shows that PMED-1 does not seem to be promiscuous by inadvertently 
effecting major kinase pathways at doses that effectively blocked β-catenin activity. 
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Figure 8. PMED-1 specifically inhibits β-catenin-CBP interactions and does not impact other common 
kinases. (A) Whole cell lysates from untreated HepG2 cells or HepG2 cells treated for 24 hours with either 2% 
DMSO, 25 µM PMED-1 or 25 µM  ICG-001 used for immunoprecipitation show significantly less CBP pull down 
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with anti-β-catenin antibody only in PMED-1 and ICG-001 treated cells by western blot analysis. (Densitometry for 
CBP provided under each band) (B) H89 decreases AKT activity in a dose dependent manner as assessed by IMAP-
based AKT FP assay. Three replicates are shown. X-axis is in log scale. (C) PMED-1 does not affect AKT activity. 
(D) H89 decreases CAK activity as assessed by IMAP-based CAK TR-Fret assay. Three replicates are shown. X-
axis is in log scale. (E) PMED-1 does not affect CAK activity. (F) H89 decreases PKD activity as assessed by 
IMAP-based PKD FP assay. Three replicates are shown. X-axis is in log scale. (G) PMED-1 does not affect PKD 
activity. (H) H89 decreases Plk1 activity as assessed by IMAP-based Plk1 TR-Fret assay. Three replicates are 
shown. X-axis is in log scale. (I) PMED-1 showed inhibitory effect on Plk1 up to -1 µM log scale (0.097 µM), 
however no decrease is evident at higher concentrations. (J) H89 decreases Plk2 activity as assessed by IMAP-based 
Plk2 TR-Fret assay. Three replicates are shown. X-axis is in log scale. (K) PMED-1 does not affect Plk2 activity. 
2.6 POSSIBLE IN VIVO APPLICATION FOR PMED-1 
When developing a novel therapeutic for possible clinical applications, there is only so 
much evidence in vitro assays can provide about in vivo efficacy and activity. Just because a SM 
does not appear to have any overt toxicity or off target effects in vitro in cell culture studies does 
not necessarily mean that the molecule will either retain its activity, or be inert considering other 
pathways in a living model. There is only so much biological function cell culture studies can 
reveal, and the only true way to ascertain the true impact a SM may have on all organ systems is 
to use in vivo models. 
2.6.1 Addressing stability of PMED-1 in vitro 
To address the stability of PMED-1 in culture and in vivo, we treated Hep3B cells that 
are stably transfected with constitutively active S33Y-β-catenin mutant with single dose of 
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PMED-1 at 25 µM for 3 hours to 48 hours as described in methods and compared its effect on 
TOPFlash reporter activity at each of these times as compared to vehicle only treatment. As seen 
in Figure 9A, beginning at 12 hours inhibition of β-catenin activity in comparison to DMSO 
control was observed. However, statistically significant, 50% inhibition of β-catenin activity was 
evident at 18-24 hours post PMED-1 treatment. At 36 hours TOPFlash activity was coming back 
to baseline. Thus, a single treatment with 25 µM PMED-1 decreased β-catenin activity as early 
as 12 hours which progressively decreased β-catenin activity until 24 hours in cell culture. 
2.6.2 Inhibition of Wnt signaling in Zebrafish with PMED-1 
To determine whether PMED-1 can inhibit Wnt/β-catenin signaling in vivo, we used the 
Tg(OTM:d2EGFP) zebrafish line which expresses destabilized GFP under the promoter 
containing six copies of Tcf/Lef binding sites (258).  For a positive control, a potent Wnt/β-
catenin signaling inhibitor, XAV939 (259), was used.  GFP expression was greatly reduced in 
91% of the Tg(OTM:d2EGFP) embryos (20 out of 22)  treated with XAV939 from 40 to 55 
hours post-fertilization (hpf) and weakly reduced in the remaining embryos compared to DMSO-
treated controls (Fig. 9B).  Importantly, GFP expression was greatly reduced in 48% of the 
embryos (12 out of 25) treated with PMED-1 compared to the controls although it appeared 
unaffected in the remaining embryos. Here, only 50% of embryos were affected by PMED-1 
likely due to its extremely hydrophobic nature which decreases its bioavailability. These data 
indicate the in vivo efficacy of PMED-1 as a Wnt/β-catenin signaling inhibitor and suggest that 
the Wnt/β-catenin inhibitory activity of PMED-1 may be weaker than that of XAV939. 
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2.6.3 Characterizing duration of Wnt signaling inhibition in vivo 
To determine how long PMED-1 can inhibit Wnt/β-catenin signaling in vivo, we 
examined GFP expression at multiple time points after PMED-1 treatment.  To better reveal 
GFP expression in Tg(OTM:d2EGFP) embryos, we used homozygous Tg(OTM:d2EGFP) 
embryos in which GFP expression is much stronger than in the hemizygous embryos.  Strong 
GFP+ Tg(OTM:d2EGFP) embryos were treated with DMSO, XAV939 or PMED-1 at 48 hpf; 6, 
12 or 24 hours later, their GFP expression was examined (Fig. 9C).  6 hours later, at 54 hpf, most 
embryos treated with XAV939 (10 out of 12) or PMED-1 (15 out of 18) exhibited reduced GFP 
expression compared to controls.  12 hours later, at 60 hpf, GFP expression was further reduced 
in XAV939-treated embryos; it was still, but not further, reduced in PMED-1-treated embryos 
(11 out of 15).  Interestingly, 24 hours later, at 72 hpf, GFP expression was significantly restored 
in PMED-1-treated embryos (8 out of 12), whereas it was still reduced in XAV939-treated 
embryos.  These data indicate that the Wnt/β-catenin inhibitory activity of PMED-1 lasts shorter 
than that of XAV939. 
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Figure 9. Efficacy and duration of PMED-1’s effect on β-catenin activity in vivo and in vitro. (A) Stably 
transfected Hep3B cells with S33Y-β-catenin, treated with a single dose of PMED-1 at 25 µM, shows gradual 
decrease in TOPFlash reporter activity becoming significant (p≤0.05) at 18 and 24 hours after treatment with 
rebound at 36 and 48 hours. (B) GFP+ embryos obtained from outcrossing Tg(OTM:d2EGFP) zebrafish were 
treated with DMSO, XAV939, or PMED-1from 40 to 55 hpf, and their GFP expression was assessed under a 
fluorescence microscope. The bottom row shows the merged images of bright field and GFP fluorescence (green) 
images. Numbers indicate the proportion of embryos showing the corresponding GFP expression. Tectum (te), retina 
(re), otic vesicle (ov), liver (li), and pectoral fin (pf). All images are dorsal view with anterior to the left. Scale bar, 
100 µm. (C) Epifluorescence images showing GFP expression in Tg(OTM:d2EGFP) embryos. Strong GFP+ 
embryos obtained from incrossing Tg(OTM:d2EGFP) zebrafish were treated with DMSO, XAV939, or PMED-
1from 48 hpf. 6, 12 or 24 hours later, these embryos were harvested and their GFP expression was assessed under a 
fluorescence microscope. Numbers indicate the proportion of embryos showing the corresponding GFP expression. 
Tectum (te), retina (re), otic vesicle (ov), liver (li), and pectoral fin (pf). All images are dorsal view with anterior to 
the left. Scale bar, 100 μm. 
2.7 DISCUSSION OF APPLICABILITY OF PMED-1 
Developing a drug from bench to bedside is an arduous and slow process. High-
throughput screens assess SMs for potential efficacy against a desired target however the 
eventual effect may be due to an off-target effect since there is little to no selectivity or 
specificity in these screens (260). The intention in these studies is to discover a molecule that 
will cause cell death in culture with little to no knowledge of the mechanism, which can then be 
tested for its efficacy in vivo. We took a novel approach by basing our drug discovery on a 
previously established SM inhibitor of β-catenin-ICG-001. Based on the premise of structure-
function similarity, we show that the PMED-1, a SM resembling the structure of ICG-001, 
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shows similar function in inhibiting β-catenin in multiple HCC cell lines although at a higher 
concentration. Like ICG-001, PMED-1 also inhibits β-catenin and CBP interactions and thus 
impedes downstream signaling. CBP is a histone acetyl transferase and interacts with β-catenin 
in the nucleus once it has been activated and has been shown to be critical for β-catenin-
dependent target gene expression (252). In addition PMED-1 did not show any off-target kinase 
inhibition against AKT, PKD, CAK, and Plk2. We also checked the quality of PMED-1 by high 
performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) to verify if 
any contaminant or a degradation product could be responsible for inhibiting β-catenin-TCF 
activity. However PMED-1 used in our studies was greater than 95% pure (data not shown). A 
major limitation with the current study was the issue of solubility of PMED-1. Being a 
hydrophobic SM, it could be only dissolved in DMSO and limited our ability to perform in vivo 
studies in orthotopic HCC models in mice. However, we were able to demonstrate its efficacy in 
a zebrafish model indicating that it is a potent β-catenin inhibitor in vivo as well. Additional 
studies will be necessary to address if modifications would be possible in PMED-1 to enhance it 
solubility and hence deliver in vivo. 
Targeting Wnt/β-catenin signaling in tumors has shown to be efficacious in preclinical 
models including use of ICG-001 in colorectal carcinoma and AV-65, another SM, in multiple 
myeloma (245, 261). In the current study we demonstrate PMED-1, another novel SM, which 
has the potential for future therapeutics in HCC or other tumors. Targeting β-catenin by PMED-
1 in HepG2 and Snu-398 cells is highly relevant because these cells have constitutively active β-
catenin owing to deletion or point mutation, respectively. PMED-1 successfully affected β-
catenin activity along with suppression of downstream Wnt targets and ensuing compromise in 
tumor cell proliferation and survival. It was interesting to note that at 48 hours HCC cells regain 
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β-catenin activity, which may suggest that half-life of PMED-1 due to its 
metabolism/inactivation or which may be due to re-growth of cells in culture that escape β-
catenin inhibition. Indeed in a time-course study both in vitro and in vivo, PMED-1 showed 
peak downregulation of β-catenin activity at 18-24 hours in cell culture and between 6-12 hours 
in zebrafish embryos. However the effects of the initial treatments can be observed in the 
lingering delay of DNA synthesis even up to 72 hours indicating that a single dose of PMED-1 
is sufficient to interrupt the β-catenin signaling cascade and in impairing the associated 
downstream biological processes. Indeed similar prolonged biological effect has been observed 
using other modalities like PNA despite recovery of some β-catenin activity (248).  
Ultimately, our work shows the practical application of in silico screening in effective 
identification of a specific molecule against β-catenin driven HCC with future therapeutic 
implications. For PMED-1 to be developed into an FDA approved compound that is clinically 
effective further investigation and optimization of its activity is required. Identifying other 
potential molecular targets of PMED-1 is crucial to our understanding of the activity and 
specificity of this compound. Biotinylating PMED-1 on an inactive subgroup will allow us to 
treat cells in culture and pull out the biotinylated PMED-1 along with any complexed molecules. 
Mass spectrometry can then be used in order to characterize what other proteins PMED-1 may 
be interacting with other than CBP. This type of investigation will also allow us to identify the 
functional group responsible for interacting with CBP to block its interaction with β-catenin. 
Knowing the functional group responsible for inhibiting CBP/β-catenin interaction is critical 
when trying to understand the activity of PMED-1. We have conducted preliminary experiments 
treating C57BL6 mice with PMED-1 in order to better understand maximum tolerated doses. 
However, the hydrophobic nature of the SM did not lend to it being readily absorbed in vivo. 
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This is where understanding the specific functional group responsible for the major activity of 
PMED-1 is important because we can then alter the chemical structure to make the SM more 
hydrophilic without inhibiting the activity of PMED-1. Making PMED-1 hydrophilic will 
increase the bioavailability in culture, as well as in vivo therefore increasing the efficacy of 
PMED-1 directed CBP/β-catenin inhibition. An additional method of increasing the 
bioavailability of a SM such as PMED-1 is by loading it onto nanoparticles which can be 
functionalized specifically to target hepatocytes (262, 263). Though the technology for 
nanoparticle based delivery systems exists, the efficacy and applicability of this type of method 
has been poorly characterized. 
Little is known about the consequences of CBP/β-catenin directed transcription. There is 
evidence that differential Wnt target gene expression may be a result of specific interaction of 
transcription factors and β-catenin in the nucleus (264, 265). In order to understand this more 
clearly, cells treated with PMED-1 can be harvested for gene array analysis which will allow us 
to understand the importance of CBP/β-catenin interaction to cellular biology.  Even though 
through structural similarity searches we have been able to discover PMED-1 as an effective SM 
that inhibits CBP/β-catenin interaction, it is important to understand the full mechanism of 
PMED-1 in order to develop a clinically applicable SM for future therapeutic implications. 
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3.0  β-CATENIN KNOCKDOWN BY CELL PERMEABLE GAMMA GUANIDINE-
BASED PEPTIDE NUCLEIC ACID REVEALS ITS NEW ROLES IN 
HEPATOCELLULAR CANCER 
When considering the development of targeted, personalized medicine in cancer, genetic 
therapies directed against an activated oncogene would be the most direct and effective method 
for an anti-tumorigenic effect. In this chapter, we report the application of second-generation 
PNA to target β-catenin. As a proof of concept, we show that targeting β-catenin not only 
impacts HCC cell proliferation and viability, which we initially show in Chapter 2, but also 
demonstrate another function of β-catenin knockdown in reducing tumor angiogenesis. This was 
shown by decreased downstream target gene expression and concomitant biological 
consequences. We show for the first time that several factors that are involved in angiogenesis 
are regulated by β-catenin signaling in HCC cells, and PNA-mediated β-catenin knockdown in 
HCC cells impairs secretion of factors that in turn affect tubulogenesis and spheroid formation 
by the HCC-associated endothelial cells. The results presented herein have important 
implications in HCC treatment and in countering drug resistance.  
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3.1 DEVELOPING AN ANTISENSE AGAINST BETA-CATENIN 
PNA is a promising class of nucleic acid mimic developed in the last two decades in 
which the naturally occurring sugar phosphodiester backbone is replaced with N-(2-aminoethyl) 
glycine units (266). PNA has many appealing features, as compared to the natural counterparts, 
including strong binding affinity and sequence selectivity towards DNA and RNA, and 
resistance to enzymatic degradation by proteases and nucleases. These properties, along with the 
ease of synthesis, make PNA an attractive molecular platform for regulating gene expression; 
however, a drawback is that it is not cell-permeable (267, 268). Previously we have shown that 
installation of a guanidinium group at the α-backbone significantly improves the cellular uptake 
of PNA (269). This new class of guanidine-based PNA (GPNA) has been successfully employed 
in the selective knockdown of E-cadherin (270, 271). More recently we reported the synthesis of 
a second-generation γGPNA, in which the guanidinium group is incorporated at the γ-backbone, 
with improved hybridization properties and economy of synthesis. Here we wanted to combine 
our experience targeting E-cadherin with the optimization of the γGPNA by targeting the β-
catenin gene in human hepatocellular carcinoma. 
3.1.1 Design and synthesis of Peptide Nucleic acids 
Inspired by the effectiveness of αGPNA in knocking-down E-cadherin in our previous 
study, we decided to target β-catenin, a well-described oncogene highly expressed in hepatoma 
cells by using the second-generation γGPNA with improved hybridization properties. We 
designed and synthesized two specific PNA sequences against the β-catenin gene, one against the 
transcription start site, called T1, and the other against the translation start site, labeled as T2 
 72 
(Fig. 10A-C). Both T1 and T2 contain regular PNA units with inserted γGPNA monomer units 
(5 units) to increase its cellular uptake properties. In order to demonstrate the selective binding of 
T1 a control PNA containing mismatch binding sites, MM was also synthesized. In order to 
examine the cellular uptake properties of designed PNA, we fluorescently labeled T1 with 
TAMRA dye. 
3.1.2 Uptake of Peptide Nucleic Acids Leads to Inhibited Wnt/β-catenin Signaling in 
HCC cells 
The human hepatoma cell line HepG2 was cultured in media containing Hoescht nuclear 
dye and 1 µM of T1 γGPNA tagged with TAMRA dye for a period of 19 hours under live cell 
imaging (Fig. 10D). Within 3 hours of T1-TAMRA treatment, a red signature appeared within 
cells. At 19 hours, T1-TAMRA was present in punctate structures, as well as within the nuclei of 
HepG2 cells. This result indicates that γGPNA is able to traverse the extracellular membrane of 
hepatoma cells on its own without the aid of a transfection reagent, or any other mechanical or 
electrical means. 
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Figure 10. Structure and sequence of antisense oligonucleotides and controls that show an unaided cellular 
uptake. (A) Chemical Structures of PNA and γGPNA. (B) Human beta-catenin (CTNNB1) gene transcript and 
location of targeted sequence and (C) Sequence of γGPNA Oligomers employed for study. (D) Human hepatoma 
cells (HepG2) were cultured in the presence of TAMRA-labeled T1 γGPNA for a period of 19 hours and the 
fluorescent dye was tracked by live cell imaging. Within 3 hours of treatment, TAMRA-T1 increased significantly 
within the cells without the aid of a transfection reagent. Cells were also incubated with Hoechst nuclear stain for 
nuclear visualization. Scale bars indicate 50 µm. 
 
Next, we assessed the antisense activities of γGPNAs against the transcription and 
translation start sites of β-catenin. To address this, we utilized the TOPFlash luciferase reporter 
to assess β-catenin-TCF activity. HepG2 cells were treated with either T1 or T2 at 5 µM for 24 
hours, 15 minutes after transfection. A 90% or 50% decrease in TOPFlash reporter activity was 
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observed after T1 and T2 treatment, respectively (Fig. 11A). In fact T1 treatment for 24 hours 
demonstrates a dose-dependent decrease in TOPFlash reporter in HepG2 cells (Fig. 11B). This 
result shows that while both γGPNAs inhibit β-catenin, T1 is more potent than T2 and was used 
for additional investigations. 
To determine the specificity of T1 γGPNA, we designed a mismatch γGPNA (MM) 
control, which differed from T1 by four base pairs (Fig. 11C). We utilized two liver tumor cell 
lines that have distinct modes of β-catenin activation. HepG2 cells harbor a deletion in exon-3 in 
β-catenin, while Snu-449 cells have a point mutation in exon-3 of CTNNB1, a common 
occurrence in human HCC (255, 257). Both cell lines were treated with 1µM of T1 for 72 hours 
to determine β-catenin inhibition over a prolonged duration. As compared to the MM control, T1 
treatment reduced TOPFlash activity significantly in both cell types (Fig. 11C-D). 
 
 
 
 75 
Figure 11. γGPNA designed against β-catenin decreases its reporter activity in hepatoma cells with T1’s 
impact being more pronounced. (A) T1- and T2-targeted against β-catenin gene transcription and translation start 
site respectively, when incubated with HepG2 cells at 5 µM for 24 hours, reduced TOPFlash reporter activity, 
although T1 had a significantly stronger effect than T2. (B) Twenty-four hour exposure of HepG2 cells to T1 
ranging from 5 µM to 50 nM exhibits a dose-response in reducing TOPFlash activity represented as ratio of Firefly 
to Renilla luciferase that in turn was normalized to no treatment control. Error bars represent standard deviation. 
(*P<0.05, **P<0.01) (C) HepG2 cells were incubated for 72 hours with 1 µM MM or T1 that led to a significant, 
sustained inhibition of β-catenin activity when analyzed by TOPFlash reporter assay. (D) Snu-449 cells, also treated 
with 1 µM MM and T1 for 72 hours, showed a reduction in β-catenin activity as assessed by TOPFlash assay. 
3.2 ANTISENSE TARGETING OF β-CATENIN AGAINST HCC IN VITRO  
As indicated in Chapter 2, targeting a signaling pathway such as the Wnt/β-catenin may 
lead to off target effects. In order to identify if T1 γGPNA treatment of HCC cell lines is as 
specific as we intend on our antisense technology to be, we can take advantage of γGPNA 
activity. Counter to the activity of PMED-1 where β-catenin activity is inhibited, but total 
protein levels remain the same, T1 γGPNA targets β-catenin at the genetic level leading to a 
reduction of protein levels and thereby a subsequent reduction in Wnt target genes. Here we 
identify this to be true by analyzing the protein and mRNA levels of β-catenin, as well as the 
downstream consequences of Wnt signaling inhibition. 
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3.2.1 PNA results in reductions of β-catenin downstream targets 
We next assessed the effects of T1 γGPNA on β-catenin gene expression and protein 
levels of β-catenin and its targets in HepG2 cells treated with 1 µM T1 or MM for 72 hours. 
Real-time PCR normalized to GAPDH showed a significant decrease in β-catenin mRNA as 
compared to MM control (p<0.05) (Fig. 12A). Western blot shows that T1 effectively reduces 
full-length and truncated forms of β-catenin in HepG2 cells and full-length form in Snu-449 cells 
(Fig. 12B). Respective lysates were also assessed for several known targets of the Wnt signaling 
pathway. A decrease in the protein expression of GS, Cyclin-D1, c-Myc, Axin-2, Regucalcin, 
and VEGF-A were evident in T1-treated HepG2 and Snu-449 cells as compared to MM control 
as shown in representative western blots (Fig. 12B). These findings further validate the efficacy 
of T1 γGPNA to successfully target β-catenin signaling in liver tumor cells. 
3.2.2 Targeting β-catenin via PNA effects HCC cell biology 
The impact on tumor cell proliferation and survival was next analyzed following T1 
γGPNA-mediated β-catenin suppression. [3H]-Thymidine incorporation assay in 1 µM T1-
treated HepG2 cells for 72 hours showed a 20% decrease in DNA synthesis or mitosis when 
compared to MM treatment indicating a significant decrease in cell proliferation (p<0.05) (Fig. 
12C). Immunofluorescence for Ki-67 (not shown), a measure of cells in S-phase of cell cycle 
was reduced by a staggering 75% (p<0.05) after T1 as compared to the MM treatment (Fig. 
12D), indicating β-catenin’s role in G1 to S phase transition by regulating expression of Cyclin-
D1.  
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Mitochondrial activity as a measure of cell metabolism and viability, was assessed by the 
MTT assay. It showed a notable decrease after 72-hour T1-treatment of HepG2 cells (Fig. 12E). 
In addition, number of apoptotic nuclei reflecting oncotic or apoptotic cell death as assessed by 
TUNEL immunohistochemistry, was significantly higher (p<0.01) after T1 treatment when 
compared to the MM group (Fig. 12F). Thus successful inhibition of β-catenin expression and 
activity by γGPNA in HepG2 cells affected tumor cell proliferation and viability.  
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Figure 12. T1 PNA treatment affects expression of β-catenin gene and Wnt target expression to impair HCC 
cell proliferation and survival. (A) When compared to MM control, the T1 treatment of HepG2 cells at 1µM for 
72 hours resulted in greater than 50% and significant (*p<0.05) decrease in β-catenin mRNA expression as seen by 
Real-Time PCR. (B) Western blots with whole cell lysates from HepG2 and Snu-449 cells treated similarly with T1 
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show decrease in β-catenin protein expression along with several of its targets as compared to MM control. (C) 
HepG2 cells incubated with 1 µM T1 or MM for 72 hours and exposed to 2.5 µCi of [5’-3H]-Thymidine for 48 
hours showed a significant decrease in DNA synthesis in T1 group. (D) HepG2 cells incubated with 1 µM T1, MM 
or no γGPNA for 72 hours and stained for Ki-67 shows a dramatic decrease in Ki-67 positive cells after T1 
treatment only. (E) A significant decrease in HepG2 viability by MTT assay was also evident after 72 hours of 1 µM 
T1 treatment as compared to MM. (F) Increased numbers of apoptotic nuclei were evident in 1 µM T1-treated 
HepG2 after 72 hours as compared to MM only. All error bars represent standard deviation. (*P<0.05, **P<0.01). 
3.3 SECONDARY ANTI-ANGIOGENIC EFFECTS DUE TO TARGETING BETA-
CATENIN IN HCC VIA PNA 
The process of angiogenesis is indispensable to tumor growth and progression. While 
Wnt signaling has been shown to be contributing to this process by mechanisms such as by 
regulating the expression of vascular endothelial growth factor (VEGF), its role in angiogenesis 
in HCC remains unexplored (253). VEGF is classically known to be a stimulator of 
angiogenesis, and has seven consensus binding sites on its promoter for the β-catenin/T-cell 
factor (TCF) complex (272). Several studies indicate the importance of VEGF in HCC 
progression and show overexpression of VEGF, and its respective receptors VEGFR-1 and 
VEGFR-2, in the tumors (200, 273). However, a direct study that investigates β-catenin 
signaling to address any impact on angiogenesis, molecularly and functionally, in HCC is 
lacking. Here we intend to answer this enigma by utilizing our optimized T1 γGPNA against β-
catenin in HCC cells. 
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3.3.1 Inhibition of β-catenin in HCC leads to inhibited expression of molecules involved in 
angiogenesis 
Wnt/β-catenin signaling is known to regulate VEGF expression in colorectal cancer (253, 
272). Indeed VEGF expression was notably downregulated after T1 treatment of HepG2 cells 
(Fig. 12B). We next interrogated if Wnt/β-catenin may be regulating other angiogenic factors in 
liver tumor cells and utilized a quantitative Real-Time PCR angiogenesis array. Intriguingly, T1 
γGPNA treatment of HepG2 cells for 72 hours led to decrease in expression of several 
angiogenic factors including CXCL5, Ephrin-A1, FGF2, IL-1b, Midkine, Placental Growth 
Factor (PGF), and SERPINF1 when compared to MM treatment (Fig. 13A). In fact, fifteen 
secreted pro-angiogenic factors showed significant differences with β-catenin inhibition with the 
exception of Heparan sulfate-cleaving enzyme heparanase (HPSE). Changes in β-catenin, 
VEGF-A, and FGF2 mRNA expression were also validated by Real-time PCR using mRNA 
from HepG2 cells treated with either 1 µM MM or T1 for 72 hours, or 50 nM of negative control 
or β-catenin siRNA for 48 hours that showed successful β-catenin knockdown along with a 
significant (p<0.01) decrease in the expression of VEGF-A and FGF2 (Fig. 13B-C).  
To further validate that VEGF-A was a major target of β-catenin in liver tumor cells we 
assessed its expression in another HCC cell line Hep3B that was stably transfected with either 
wild-type or serine-33 to tyrosine (S33Y)-mutated β-catenin. A robust increase in the expression 
of VEGF-A was evident in Hep3B cells harboring S33Y mutant β-catenin (Fig. 13D). Thus 
VEGF-A expression is regulated by β-catenin in HCC cells. 
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Figure 13. Modulation of β-catenin regulates expression of angiogenic factors in HCC cells. (A) Quantitative 
RT-PCR angiogenesis array on mRNA isolated from HepG2 cells treated with 1 µM MM or T1 for 72 hours reveals 
a notable decrease in expression of several secreted pro-angiogenic factors. (B) Additional validation by Real-Time 
PCR shows significant decreases in the expression of β-catenin and concomitantly of FGF2 and VEGF-A (p<0.01) 
after T1 and not MM treatment of HepG2 cells. (C) Results were also verified by Real-Time PCR on mRNA from 
HepG2 cells transfected with β-catenin or control siRNA that showed significant decreases in β-catenin, FGF2 and 
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VEGF-A expression (p<0.01). (D) Hep3B cells stably transfected with S33Y-mutated and not wild-type (WT) β-
catenin shows notable increase in β-catenin and VEGF-A expression. 
 
3.3.2 Reduced expression of angiogenic factors due to β-catenin directed PNA treatment 
leads to inhibition of angiogenesis in endothelial cells 
We next investigated if decreased expression of various angiogenic factors observed after 
β-catenin inhibition is functionally relevant and could hinder HCC-associated angiogenesis. We 
utilized SK-Hep1 cells, an endothelial cell line derived from a hepatic adenocarcinoma (274). 
We generated endothelial spheroids which, after embedding in collagen gels, were grown in 
conditioned media taken from HepG2 cells after either MM or T1 γGPNA treatment as 
described in methods (Fig. 14A). A significant decrease in the numbers of tubes sprouts (p<0.01) 
from the SK-Hep1 spheroids was evident when cultured in T1-conditioned media as compared to 
the MM control for 24 hours (Fig. 14B). Likewise, the tube sprouts that did form from the 
spheroids in the T1-conditioned media showed a significant decrease (p<0.05) in length as 
compared to the MM control (Fig. 14C). Additionally, SK-Hep1 cells were cultured on an 
extracellular matrix that promotes tubule formation of endothelial cells. When SK-Hep1 cells 
were grown for 3 hours in the conditioned media from T1-treated HepG2 cells, there was a 
dramatic decrease in tube formation as compared to the ones cultured in the conditioned media 
from MM treated HepG2 cells (Fig. 14D). We next assessed the tube length from each 
condition. There was a statistically significant decrease in average tube length in T1 group 
versus MM (p<0.05) (Fig. 14E). Additionally, number of tubes that were 4 µm in length or more 
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was significant fewer (p<0.05) when cultured in conditioned media from T1-treated HepG2 cells 
(Fig. 14F).  
In order to address if the conditioned media used in spheroid and tubulogenesis assays 
could have any leftover γGPNA, which may directly affect β-catenin activity in the endothelial 
cells, HepG2 cells were transfected with TOPFlash and cultured for 24 hours in the same 
conditioned media used in assays above. Comparable TOPFlash activity verified an absence of 
any residual T1 γGPNA in the conditioned media (Fig. 14G). Thus, β-catenin suppression in 
liver tumor cells impairs growth and development of tumor-associated endothelial cells in a 
paracrine manner. 
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Figure 14. Conditioned media from single T1 treatment of HepG2 cells collected after 72 hours diminished 
angiogenesis in SK-Hep1 cells. (A) SK-Hep1 endothelial spheroids incubated with conditioned media obtained 
from HepG2 cells cultured in the presence of T1 or MM for 72 hours show dramatically less branching in T1. (B) 
Numbers of tube sprouts from each spheroid were counted. Comparison of averages (MM n=3; T1 n=4) (+/-SD) 
showed a significant decrease in number of sprouts in the T1 group (**p < 0.01). (C) Average tube length (+/-SD) 
from SK-Hep1 endothelial spheroids (MM n=3; T1 n=4) also showed a significant less length in T1 group (*p < 
0.05). (D) Two representative phase contrast images each from SK-Hep1 cells incubated for 3 hours on extracellular 
matrix while cultured in either conditioned media from HepG2 cells treated with MM γGPNA or T1 γGPNA for 72 
hours, show a noteworthy inhibition in tube formation and connections in the presence of T1-conditioned media 
only. (E) Quantification of tube length from conditions described in D shows a significant decrease in average 
length of tubes formed by SK-Hep1 cells when cultured in conditioned media from HepG2 cells treated with T1 
γGPNA (*p<0.05). (F) Number of tubes measuring greater than 150 µm were also significantly lower in T1 as 
compared to the MM group (**p<0.01). (G) The same conditioned media used for A and D, when utilized to culture 
HepG2 cells showed comparable and low TOPFlash activity indicating lack of unused T1 γGPNA in the media that 
could have influenced endothelial cell function to confound angiogenesis assays. 
3.4 DISCUSSION OF THE SIGNIFICANCE FOR DEVELOPMENT OF ANTISENSE 
FOR THERAPEUTICS 
PNA is a particularly promising class of nucleic acid analogue, developed in early 
1990’s, in which the natural sugar-phosphodiester backbone is substituted with achiral N-(2-
aminoethyl) glycine units (266). The neutral backbone contribute the outstanding features to 
PNA which include 1) strong hybridization with complementary DNA and RNA with high 
affinity (and sequence selectivity) through Watson-Crick base pairing and 2) resistance to 
enzymatic degradation by proteases and nucleases (275, 276). These significant properties have 
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made PNA an attractive reagent for many applications in biology and medicine. However, poor 
cell-permeability remains a challenge for PNA (267, 268). Our group has reported a second-
generation γGPNA, which can be prepared from a relatively cheap L-arginine and exhibits better 
hybridization and cellular uptake properties (277). These γGPNA oligomers are already 
conformationally pre-organized into a right-handed helix and are capable of binding DNA and 
RNA with high affinity and sequence selectivity, and we have already demonstrated that these 
can be taken-up by cells. Our studies indicate that within the first few hours of treatment, 
γGPNA localizes to both nucleus and cytoplasm, where it can interact with mature mRNA.  
Utilizing this new class of antisense molecules, we demonstrate a clear efficacy of β-
catenin γGPNA, both directed against the transcription start site (T1) as well as against the 
translational start site (T2) of CTNNB1. The effect of T1 was greater than T2 and is in agreement 
with previous studies (278). Using two liver tumor cell lines that harbors either a β-catenin gene 
deletion or a point mutation we demonstrate the efficacy of T1 to inhibit β-catenin gene 
expression, protein and activity. The effect of γGPNA treatment on tumor cells in culture was 
more robust at 24 hours than 72 hours. This is likely due to the lack of uptake of the γGPNA by 
all cells in culture, giving such cells a growth and survival advantage over 72 hours. However, 
overall impact on tumor cell proliferation, viability and apoptosis was significant as has also 
been reported previously (Reviewed in (183)). The suppression of β-catenin activity after 72 
hours of γGPNA treatment on HepG2 cells was less robust as compared to Snu-449 cells. HepG2 
HCC cells have a monoallelic, truncated β-catenin, which lacks exon-3 that contains all 
phosphorylation sites (serine 33, 27, 45 and threonine 41) required for degradation of β-catenin 
by the ubiquitin proteasome. Snu-449 cells have a single point mutation affecting serine 37, 
which also renders β-catenin stable. It is likely that the difference in stability of truncated versus 
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point-mutant β-catenin may be accounting for the difference in extent of decrease in β-catenin 
activity in response to the γGPNA mediated β-catenin knockdown. Thus, we have developed 
γGPNAs as a class of novel agents that could have significant therapeutic efficacy in targeting a 
specific molecule and at the same time have characterized a link between Wnt/β-catenin 
signaling and tumor angiogenesis in liver cancer. 
In the current study we show that β-catenin suppression in HCC cells impairs the 
expression of several secreted pro-angiogenic factors that may be released by the tumor cells to 
influence angiogenesis in a paracrine manner. We identified decrease in various factors such as 
VEGF-A, Ephrin, FGF2, and CXCL5 after β-catenin suppression in liver tumor cells that are 
known to be relevant in HCC tumor angiogenesis (279). VEGF-A has been noted to be a direct 
target of β-catenin in colorectal cancer (253). It was interesting to note that FGF2 was decreased 
by both β-catenin-directed siRNA and γGPNA to the same extent, although β-catenin 
suppression was much more robust in the former modality. This could be due to an 
autoregulation by FGF2 that has been described previously (280). Intriguingly, we saw an 
increase in HPSE expression after β-catenin knockdown by T1 PNA treatment for 72 hours. 
Since this enzyme cleaves heparan sulfate in extracellular matrix, it has been associated with 
increased metastasis and angiogenesis. However, several other pro-angiogenic secreted factors 
were decreased as a result of β-catenin inhibition. This demonstrates a paracrine mechanism by 
which β-catenin activation in HCC could be supporting tumor growth and progression. Indeed 
the conditioned media from HCC cells cultured in the presence of T1 γGPNA was insufficient to 
support the growth and development of HCC-associated endothelial cells. An earlier study has 
also shown adenoviral mediated inhibition of Wnt signaling by Wnt inhibitory factor 1 (WIF1) 
and secreted frizzled-related protein 1 (sFRP1) overexpression in endothelial cell progenitors 
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impacted their differentiation and induced apoptosis (281). Thus, we conclude that β-catenin 
inhibition may in fact have dual impact on angiogenesis by not only interfering with growth and 
differentiation of endothelial progenitor cells directly but also via inhibiting paracrine signaling 
emanating from HCC cells.  
When considering novel therapeutics, antisense technologies are among the most 
specific. Our PNA antisense is stable, effective and specific enough to reduce β-catenin protein 
expression in HCC cells leading to compromised cell growth and survival. There are several 
studies that indicate specific mutations in the DNA encoding for β-catenin which result in 
constitutive activation in HCC patients (163, 175, 189, 190). We have an HCC cell line with one 
of these genetic mutations cloned and being stably expressed utilized in this study, Hep3B-S33Y. 
In order to validate the specificity of our PNA antisense, we can clone out other known β-catenin 
mutations observed in HCC patients and create stable cell lines with these mutations as well. 
This will allow us to engineer PNA against these specific genetic mutations and can be tested by 
using the TOPflash luciferase assay.  We could then analyze for off target effects of specific 
engineered PNA which may target a genetic mutation that it initially was not designed for. 
Ultimately, utilizing these PNAs in an in vivo model of HCC where activating β-catenin 
mutations drive the disease would be monumental achievement. However, what limits 
developing PNA for biological applications is the lack of optimized techniques for large scale 
synthesis of PNA. It is a very cost inefficient and labor intensive process to construct PNA 
oligonucleotides, and biological characterization will be slow until effective synthesis techniques 
for producing large quantities of PNA is developed. 
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4.0  ANTISENSE LOCKED NUCLEIC ACIDS TREAT BETA-CATENIN DRIVEN 
HEPATOCELLULAR CARCINOMA IN MICE 
Personalized medicine is beginning to make a significant presence in the battle against 
cancer. It is defined by the identification of a specific cause of a patient’s disease, which can be 
precisely targeted resulting in a reduction of disease burden without overt toxicity. When 
considering the future of cancer therapeutics, the ideal method of therapy would be to 
specifically identify one or several factors driving the disease and target only these aberrations. 
Currently, groups including ours, such as in Chapter 3, have been pursing antisense 
technologies for their potential to be tailored against a specific gene of interest. An interesting 
form of antisense oligonucleotide currently emerging is the Locked Nucleic Acids (LNAs). In 
this chapter we report the utilization of a novel LNA directed specifically against β-catenin in 
mouse models of HCC. Using a mouse model, which results in hepatocarcinogenesis secondary 
to activated β-catenin activation, we demonstrate that administration of LNA against the β-
catenin gene to mice with established tumors resulted in a significant decrease in downstream 
Wnt target gene expression along with a notable reduction in tumor burden. The results 
presented here provide the final proof-of-concept therapeutic implications of targeting activated 
β-catenin in cancers like HCC for personalized medicine, to hence pave the way for the use of 
antisense oligonucleotides as a practical therapeutic modality.  
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4.1 USE OF LNA LEADS TO REDUCED WNT/BETA-CATENIN SIGNALING 
Two independent groups were responsible for the initial synthesis and characterization of 
LNA oligonucleotides in the late 1990’s to early 2000’s. As opposed to normal DNA or RNA 
nucleotides, LNA nucleotides have a methylene bridge that “locks” the 2P-oxygen in the ribose 
backbone to the 4P-carbon (Fig. 15) (282-284). The bridge created actually stabilizes the 
position of the phosphate backbone in an LNA oligonucleotide resulting in superior 
hybridization with DNA or RNA (282-284). Because LNA can easily hybridize with an intended 
DNA or RNA target of interest, inhibition of gene expression can occur via the activation of the 
RNase H recognition and degradation pathway (285, 286). The activation of the RNase H 
pathway gives LNA its antisense effect, and we have shown in Chapter 3 the applicability of 
γGPNA as an antisense technology used to block β-catenin protein expression in HCC cell lines 
leading to inhibited cell viability. However, compared to γGPNA synthesis, an attractive aspect 
about LNA is the synthesis of LNA is identical to the polymerization of DNA or RNA only 
differing in the locked monomeric units. This can allow for large-scale synthesis of LNA that is 
relevant especially for in vivo use. In this section we characterize the impact of β-catenin 
directed LNA in vivo in normal and tumor-bearing mice to assess and optimize its efficacy in 
reducing β-catenin expression and activity. 
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Figure 15. Nucleotide structures for LNA (A), DNA (B), and RNA (C). 
4.1.1 Optimization of LNA treatment in vivo in mouse liver 
In order to assess the efficacy of LNA treatment in vivo, we treated wild type C3H/He 
mice with 15 mg/kg (n=3) or 30 mg/kg (n=1) EZN-3892 (directed against β-catenin), and 
compared these mice to 15 mg/kg EZN-3046 (directed against a scrambled sequence of survivin 
gene) treated mice (n=2) (Fig. 16A). Mice were treated every other day for a total of five times 
and monitored for toxicity. End of study liver weight to body weight (LW:BW) ratio showed no 
significant difference between the control and experimental group (Fig. 16B). Total β-catenin 
protein expression in whole liver lysates was significantly inhibited after EZN-3892 LNA 
treatment compared to the control group with contaminant reduction of GS protein expression, 
the hallmark indicator of β-catenin co-transcriptional activity in the liver (Fig. 16C). 
Immunohistochemical (IHC) analysis of liver sections confirmed a visible decrease in total β-
catenin levels throughout the liver as well as notably lower GS expression in the pericentral zone 
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of the liver (Fig. 16D). Thus, our analysis indicates that EZN-3892 (β-catenin antisense LNA) 
treatment is a suitable tool to reduce β-catenin expression in mice leading to significant 
inhibition of Wnt/β-catenin activity. 
 
 
Figure 16. LNA administration significantly reduces β-catenin and GS levels in normal mice. (A) Schematic 
representation of LNA administration. Mice were given 15 mg/kg of either ENZ-3046 (Scrambled Survivin) or 
EZN-3892 (β-catenin) directed LNA five times every 48 hours prior to harvesting and processing for analysis. (B) 
Following LNA administration, mice livers when compared to their respective body weights did not differ when 
considering 15 mg/kg of ENZ-3046, 15 mg/kg EZN-3896, or a high dose of 30 mg/kg EZN-3896 indicating no 
significant gross toxicity. (C) Protein levels for β-catenin and GS were significantly reduced following EZN-3892 
administration. (D) Immunohistochemistry also shows reduced levels of β-catenin and GS especially around the 
pericentral regions of the liver. 
 93 
4.2 ESTABLISHING A WNT/β-CATENIN DRIVEN HCC MODEL IN VIVO 
There are many mouse models of HCC currently available to researchers, but there are 
only few which represent clinically observed β-catenin activation in patients (189, 246, 287-
291). The most clinically relevant mouse model which gives an accurate representation of the 
steps to carcinogenesis leading to activated β-catenin driven HCC is one which is induced by a 
chemical carcinogen called DEN, and then carcinogenesis is promoted by an activator of the 
constitutive active androstane receptor (CAR) called Phenobarbital (PB) leading to increased 
hepatocyte proliferation (173, 287, 292). DEN is bioactivated by two enzymes present in 
pericentral hepatocytes, Cytochrome P450 enzyme 2E1 (CYP2E1) and 2A6 (CYP2A6), causing 
its subsequent hydroxylation and oxidation, respectively, leading to the generation of genotoxic 
products which initiate DNA adducts and potentiate mutagenesis (293-297). PB is a barbiturate 
traditionally used as an antiepileptic. When administered orally, PB is absorbed through the 
portal circulation where it binds to Epidermal Growth Factor Receptor (EGFR) and blocks 
Epidermal Growth Factor (EGF) signaling, subsequently promoting the activating 
dephosphorylation of CAR which stimulates its transcriptional activity in hepatocytes (298-301). 
In this section we recapitulate the combination of DEN and PB mouse model albeit with 
administration at later stages and prove its quintessential use as a model of clinically observed, 
activated β-catenin in HCC. 
4.2.1 Characterizing biological impact of DEN with PB in mouse liver 
C3H/He mice were stratified into four groups of three mice each, Wild Type (WT), DEN 
only, PB only, and DEN+PB (DP), and were administered DEN and PB as indicated in methods 
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following which the mice were housed for roughly six additional months (Fig. 17A). During the 
course of the model there were some fatalities of unknown causes resulting in groups of mice 
being 2, 3, 2, and 2 respectively at the end of the study. After analysis of LW:BW ratio, the mice 
under the DP model had a higher LW:BW compared to the other three groups although statistics 
could not be done due to low numbers (Fig. 17B). Gross morphology of DP mouse livers reveals 
significant tumor burden as well compared to WT, DEN, or PB groups thus proving the efficacy 
of this model to induce hepatocarcinogenesis in mice under a relatively reasonable time frame 
(Fig. 17C). 
 
 
Figure 17. Successful recapitulation of DP model leads to HCC tumor burden. (A) Schematic representation of 
tumor model. 6 week old mice were injected with 90 mg/kg DEN followed by 3 weeks of rest. After, mice were put 
on 0.05% Phenobarbital diet for 24 weeks and mouse livers were harvested for analysis. (B) Average mouse 
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LW:BW ratio as compared to No Treatment group showed increase in liver weight in DP model as a result of tumor 
burden. (C) Representative gross images of mouse livers show DP group with significant HCC tumor burden. 
4.2.2 Histological and protein confirmation of activated β-catenin in carcinogenesis model 
Upon histological investigation of the β-catenin status in each group of mice, the 
DEN+PB group showed prototypical hallmarks of β-catenin activation such as cytoplasmic and 
nuclear localization in tumor nodules (Fig. 18A). Concomitantly, nodules present in DP mice 
were all significantly positive for GS staining, with exception to two nodules visibly negative for 
GS, indicating activated Wnt/β-catenin signaling in majority of the tumor nodules (Fig. 18B). 
Indeed this protocol was shown to select for β-catenin-activation in 90% of HCCs (173). GS 
positive nodules were quantified per slide section per mouse and further indicate significant 
tumor burden from Wnt/β-catenin activation in DP mice (Fig. 18C). Data not shown here 
verified presence of S33Y mutations in many tumor nodules in this model. This data indicates 
our ability to successfully reestablish a model of HCC where Wnt/β-catenin seems to be the 
driving oncogenic signaling pathway.  
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Figure 18. Histological analysis of β-catenin driven HCC in DP murine model. (A) IHC for β-catenin indicates 
nuclear/cytoplasmic presence in DP group only. (B) IHC for GS indicates tumors positive for nuclear/cytoplasmic 
β-catenin are also positive for GS staining. (C) Quantification of the number of GS positive and GS negative tumors 
per slide section in each group indicates GS positive nodules are exclusive to DP group. 
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4.3 USE OF LNA IN HCC MODEL LEADS TO REDUCED WNT/β-CATENIN 
SIGNALING AND TUMOR BURDEN 
We have previously demonstrated the utilization of antisense oligonucleotides, which 
significantly inhibits HCC cell survival and subsequent secondary pathways such as those with 
effect on angiogenesis after targeting β-catenin in Chapter 3. Other studies have also proven the 
usefulness of antisense such as morpholinos in targeting Wnt/β-catenin signaling in culture as 
well as during rat liver regeneration (302). No such technology has been successfully been 
applied against Wnt/β-catenin driven HCC in vivo. Here we show for the first time that solely 
targeting β-catenin with antisense LNA in a mouse model of HCC with activated Wnt/β-catenin 
suppresses established tumor burden leading to significant disease regression. 
4.3.1 Baseline characterization of livers following LNA treatment under DEN + 
Phenobarbital model 
C3H/He mice were stratified into 7 groups as summarized in Appendix C. Briefly, these 
included WT given 15 mg/kg ENZ-3046 (WTC) (3), WT given 15 mg/kg ENZ-3892 (WTβ) (3), 
DEN+PB (DP) (5), DEN+PB given 15 mg/kg ENZ-3046 (DPC) (7), DEN+PB given 0.03 mg/kg 
ENZ-3046 (DPCL) (5), DEN+PB given 15 mg/kg ENZ-3892 (DPβ) (8), and DEN+PB given 
0.03 mg/kg ENZ-3892 (DPβL) (4) (Fig. 19A). Mice were treated ten times every other day and 
monitored for toxicity. One mouse in group WTβ died from unknown causes, while two mice, 
one each in groups DPC and DPβ, died from anesthesia following the 8th injection of LNA. 
Baseline characterization began with identifying the β-catenin and GS expression in each group 
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(Fig. 19B). Histological examination of livers showed some heterogeneity in tumor development 
in the control groups whereas other show mostly homogeneous nodules in the DPC and DPCL 
groups as noted by uniformly GS positive nodules. One mouse each from DPC and DPCL 
groups did not present obvious GS positive nodules and therefore were omitted from further 
analysis. Remaining mice after omission in DPC (5) and DPCL (4) were considered together 
because regardless of dose, administration of scrambled control antisense oligonucleotides did 
not affect hepatocarcinogenesis or tumor biology. Also, tumor burden in DPβL group as 
identified by GS and nuclear/cytoplasmic β-catenin presence did not reduce under IHC when 
compared to DP, DPC, or DPCL groups (data not shown) therefore the DPβL group was also 
omitted from future quantitation and analysis. Ultimately, tumor burden as quantified by the 
presence of GS positive nodules was significantly reduced in the DPβ group compared to the DP 
and DPC groups (Fig. 19B). 
Following administration of β-catenin-directed LNA, significant decreases in expression 
of both β-catenin and GS was observed in the DPβ group as compared to DPC or DP groups by 
Western Blot analysis (Fig. 19C). Tumor burden was assessed by H&E to analyze the presence 
of HCC tumors, which were significantly reduced in the DPβ group only (Fig. 19D). The most 
striking observation was absence of GS-positive nodules in the DPβ group by IHC as compared 
to DP and DPC groups (Fig. 19D). This indicates a inhibition of Wnt/β-catenin activation in 
DPβ group as shown by IHC (Fig. 19E). These data together suggest that β-catenin directed 
LNA alone is not only sufficient to reduce protein levels but also its activation, leading to 
decreased expression of GS, subsequently leading to regression of established HCC tumors in 
vivo. 
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Figure 19. Inhibiting β-catenin expression via LNA treatment reduces tumor burden following DEN+PB 
carcinogenesis model. (A) Schematic representing LNA treatment after DEN+PB tumorigenesis. C3H/He mice 
injected at 6 weeks old with 90 mg/kg of DEN followed by a 3 week reprieve which led to 6-8 months on 0.05% PB 
diet. Mice were then categorized in 5 groups representing 0.03 or 15 mg/kg of EZN-3046 or EZN-3892, as well as a 
group not treated with LNA. Injections occurred 10 times every 48 hours leading to harvesting of mouse livers for 
examination. (B) Tumor burden is quantified as average number of GS positive nodules per slide section per group. 
(C) Western blot for β-catenin and GS protein expressions compared to GAPDH in whole liver lysates showing 
significant reductions following EZN-3892 LNA administration in mice under DEN+PB model. (D) H&E and GS 
immunohistochemistry of whole liver sections shows significant reductions in GS tumor burden following EZN-
3892 LNA administration compared to no treatment, or EZN-3046 LNA.(E) IHC for β-catenin indicates 
significantly reduced nuclear/cytoplasmic β-catenin presence following EZN-3892 LNA administration. 
 
4.4 DISCUSSING POSSIBLE THERAPUTIC IMPLICATIONS OF LNA ANTISENSE 
IN LIVER CANCER 
Originally, LNA oligonucleotides were used as molecular probes for microarray gene 
analysis because of their high binding affinity to DNA and RNA (303-305). Researchers began 
to test biological applications of LNA in cells such as inhibiting expression of telomerase 
showing not only their efficacy in vitro, but that they can easily transfected into cells by known 
lipophilic methods (306). Eventually chemotherapeutic implications were realized when in vivo 
experiments were performed targeting a subunit of RNA polymerase and showed that mice 
treated with LNA against this gene resulted in reduced tumor burden (307). As far back as 2001 
LNA and antisense technology was proposed for possible chemotherapeutic applications (308). 
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Currently there are several companies dedicated to developing LNA antisense technologies for 
therapeutics, and several clinical trials are underway (309). The ease of LNA synthesis and its 
mass production makes it an attractive modality for specifically targeting known oncogenes 
driving cancer progression for personalized medicine. Indeed, concepts of personalized medicine 
have been applied from thyroid cancer treatment to antiretroviral medicines for HIV, and even in 
regenerative medicine (310-312). In the current study we show that targeting active Wnt/β-
catenin signaling in HCC using LNA antisense technology may be another relevant application 
personalized medicine.  
Activation of Wnt/β-catenin signaling pathway in primary HCC is heterogeneous making 
its targeting a challenge (254, 313). However, we have indicated in the previous chapters that 
inhibiting β-catenin activity in HCC cells either by reducing its nuclear activity by SM, or 
inhibiting its expression by antisense γGPNA, leads to significant impact on tumor cell survival, 
proliferation and other processes such as angiogenesis (248). In this current study, we use LNA 
antisense in a successfully recapitulated in vivo model of HCC where β-catenin mutations drive 
tumorigenesis. Ablation of β-catenin expression alone was able to dramatically lower tumor 
burden in this model (Fig. 19).  
We know through our studies that inhibiting β-catenin protein expression via LNA 
antisense technology leads to a reduction in HCC disease burden in mice. What we currently do 
not understand are the consequences which follow after β-catenin protein expression is reduced 
in these HCC tumors. What we do know is that β-catenin in hepatocytes is responsible for 
regulating the expression of GS and proteins involved in angiogenesis as previously described in 
Chapter 3. GS and angiogenesis are critical to cell viability and survival, therefore animals with 
HCC treated with antisense LNA against β-catenin should experience significant levels of 
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apoptosis leading to a potential inflammatory response to clear the dead cells. Apoptosis can be 
evaluated by TUNEL staining while the type of inflammatory response can assessed for 
TH1/TH2/TH17 by analyzing interferon-γ, IL4/5, or IL17 presence respectively by PCR, 
immunohistochemistry, or by fluorescence-activated cell sorting (FACS) analysis. 
An additional question our DEN+PB model can be used to address is the origin of the β-
catenin driven tumor cells which lead to their significant expression of GS. Interestingly, it is 
well known that the only cells that express GS at detectable levels by immunohistochemistry are 
those in the pericentral zone of the liver (314). Additionally, evidence suggests the pericentral 
hepatocytes are the only cells in the liver which express the necessary CYPs which metabolize 
and activate DEN, and express targets related to Phenobarbital administration (293-297, 301). 
With this being said, in situ hybridization of β-catenin through the duration of tumorigenesis 
under DEN+PB will allow us to observe if cells in the liver have copy number variations in the 
β-catenin gene. Analysis of loss of heterozygosity (LOH) will also give information when 
genetic aberrations become present.  
While the precise mechanism of how β-catenin ablation leads to reduced tumor burden is 
currently not known, it is likely that through regulation of its downstream targets, it may have 
multitude of effects on tumor cell proliferation and viability due to effects on metabolism, 
angiogenesis and even cancer stem cell expansion. Considering how other forms of LNA 
antisense therapy are in clinical trials, for example in castration-resistant prostate cancer, LNA-
based anti β-catenin therapy may be feasible in a subset of HCC cases (309). 
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5.0  CONCLUSIONS AND FUTURE PROSPECTS 
5.1 TARGETING β-CATENIN IN HCC: A SAFE BET? 
Identification of signaling pathways that are aberrantly active in tumor cells only, form 
the basis of personalized therapy and hold promise of fewer side effects. However, a lingering 
concern remains whether pathway like Wnt/β-catenin signaling that is critical in so many aspects 
of normal biology ranging from maintenance of the stem cell niche, to retention of cell-cell 
adhesions, could be druggable (315, 316). This is also a plausible concern since β-catenin is all 
part of the adherens junctions assembly. There are several theoretical arguments that demonstrate 
the safety of β-catenin inhibition especially in the liver. Liver-specific β-catenin conditional KO 
mice are viable and show no overt phenotype (317). Acute or chronic loss of β-catenin in liver or 
HCC cells is spontaneously compensated by γ-catenin albeit only at the adherens junctions (316, 
318). Furthermore, liver is a unique organ in its dual blood supply that is derived from portal 
vein (~75%) and hepatic artery (25%). Interestingly, most HCCs are fed by the hepatic artery 
making loco-regional procedures such as TACE, viable and safe therapeutic modalities. Hence 
one can envision use of anti-β-catenin agent to be delivered via such a procedure. Additionally, 
nanoparticle-based delivery or another method may have its own advantage to reduce any 
systemic toxic effects (319). Another caveat to this type of directed therapy is the fact that tumor 
cells may be able to activate alternate mechanisms of escape or resistance to a directed therapy. 
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We have shown that another oncogenic pathway, PDGFRα, is upregulated in HCC when Wnt/β-
catenin signaling is suppressed (198, 320). And in such a case a sequential or combinatorial 
therapy may be useful. Thus, targeting activated Wnt/β-catenin signaling in HCC is plausible 
and may be safe and beneficial at least in a major subset of tumors.  
5.2 USING SMALL MOLECULES FOR HCC THERAPY 
HCC has a 90% fatality rate worldwide due to lack of an effective treatment (1, 19). HCC 
is currently the seventh most common cancer in the world and number three in cancer-related 
deaths (1, 19). With the current global burden of HCC, it is paramount to develop an effective 
therapy to treat the disease. Surgical resection and liver transplantation is a desirable therapeutic 
approach as it may be curative and also replaces cirrhotic liver with disease-free donor liver (22, 
23). However, due to lack of resources, not every HCC patient can receive a liver transplant.  
As discussed above, being a highly vascularized tumor, TACE is also useful in delivering 
chemotherapeutic agents in select patients with unresectable HCC (193). Eventually, owing to 
increased expression of VEGFR and PDGFR signaling, HCC has been shown to be somewhat 
susceptible to multi-TKIs (198-200). Sorafenib, a prototypical kinase inhibitor is used currently 
to treat unresectable primary HCC, with some therapeutic benefit (321). Sorafenib use in HCC 
patients has been shown to improve overall survival in advanced HCC patients, although it has 
limited efficacy especially in Child Pugh B and is often not well tolerated by patients (321, 322). 
Additionally Sorafenib targets multiple receptor tyrosine kinases including VEFGR, PDGFR and 
also Raf serine/threonine kinases eventually impacting the MAPK signaling. However, a distinct 
pathway implicated in hepatocarcinogenesis is the Wnt/β-catenin signaling pathway, which is 
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active in a significant subset of HCC due to various reasons. Thus, developing targeted therapies 
for HCC could significantly benefit patients with unresectable, primary HCC. Perhaps the most 
functional mechanism leading to constitutively active β-catenin in HCC is mutations in 
CTNNB1 and AXIN1/2, which interfere with its degradation resulting in nuclear translocation 
and increased target gene expression. These targets play various roles in tumor cell biology 
including regulation of tumor cell proliferation, survival, angiogenesis, and metabolism. 
Therefore inhibition of β-catenin in a subset of HCC is expected to be of significant therapeutic 
relevance. However, there are no effective inhibitors of β-catenin approved for clinical use and 
hence there is a need to drug discovery against this molecule. 
We have developed a novel Wnt/β-catenin signaling inhibitor based off the structure of a 
known β-catenin inhibitor, ICG-001. Our SM is capable of inhibiting β-catenin driven 
downstream target expression which leads to subsequent inhibitions in cell survival and 
proliferation. Even though our SM has a limited efficacy observed in vitro, the potential for this 
molecule to be delivered through TACE is high. TACE delivers chemotherapeutic agents 
directly to the site of the lesion in the liver, allowing us to deliver PMED-1 directly to the site of 
interest. PMED-1’s 24 hour activity is a benefit in this situation because while most of the SMs 
effect will be on the local area, once the SM disseminates systemically most of its activity will be 
gone indicating low to moderate off target toxicities. PMED-1 may have applications in other 
pathologies with activated Wnt/β-catenin signaling such as colorectal carcinoma and certain 
melanomas. With further optimization and characterization, PMED-1 may be a new therapeutic 
SM targeting Wnt signaling in diseases. 
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5.3 ANTISENSE THERAPY TARGETING β-CATENIN IN HCC 
Heterogeneity in signaling mechanisms among individuals is the thought behind 
personalized medicine. Several classes of signaling pathways have been identified to be 
aberrantly active in HCC making them attractive therapeutic targets. Wnt/β-catenin signaling is 
considered to be one of those pathways (183). While multiple modes of β-catenin activation have 
been reported in HCC, a major mechanism is mutations in CTNNB1, which leads to formation of 
stable β-catenin protein and has been shown to be associated with tumor proliferation, invasion, 
growth and viability (254, 313). In addition, based on the premise that cancer stem cells in HCC 
demonstrate active β-catenin signaling, its inhibition will impair the major cell source 
responsible for resistance, recurrence and metastasis (323-325). Concomitantly, based on the role 
of mutated-β-catenin in making a subset of HCCs glutamine-addicted, β-catenin inhibitors may 
impair tumor metabolism to eventually affect tumor growth and survival (326). Thus, any 
strategy that would suppress β-catenin expression may have a therapeutic benefit in HCC. Indeed 
anti-β-catenin therapies are being increasingly discussed and some agents are in various stages of 
preclinical and clinical development (327, 328). The role of β-catenin signaling however remains 
unexplored in HCC tumor angiogenesis and we now report regulation of several key angiogenic 
factors by the Wnt signaling, broadening the advantages of targeting β-catenin therapy in this 
tumor type. In fact we use a novel and timely modality, a new generation of γGPNA, to inhibit β-
catenin signaling and demonstrate its impact on angiogenesis.  
As an added effect of inhibiting β-catenin activity in HCC cells, the expression of several 
targets involved in angiogenesis, were significantly inhibited leading to suppression of 
angiogenesis in SK-Hep1 endothelial cells which has never been shown before. Like many other 
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solid tumors, angiogenesis is also relevant in HCC. Growth and progression of hepatic tumors 
requires formation of new blood vessels as a source of nutrients and for effective metabolism 
(279).  One of the potential mechanisms of the approved drug Sorafenib for stage IV 
unresectable HCC is its impact on angiogenesis through inhibition of certain receptor tyrosine 
kinases such as VEGFR2 (Flk1), platelet derived growth factor receptor (PDGFR) and others 
(329). However, angiogenesis inhibitors by themselves have had a limited impact on clinical 
outcome of HCC, which has been blamed on tumor heterogeneity in terms of areas of 
hypovascularity and hypoxia within tumors, and also on the hypoxia induced by the anti-
angiogenic therapy. Hypoxia indeed has been shown to be a major driver of HCC growth as well 
as in imparting chemoresistance. Intriguingly, judicious use of anti-angiogenesis inhibitors as an 
adjuvant therapy has been shown to improve overall outcome in HCC patients. Similarly, agents 
such as Sorafenib, which impact multiple aspects of tumorigenesis including growth and 
viability of cancer cells and tumor angiogenesis has already shown a promise in HCC treatment. 
Our current study shows that therapeutic targeting of β-catenin may also have a similar broader 
impact in select HCC patients with activating mutations in CTNNB1 or other mechanisms that 
lead to β-catenin activation by not only directly targeting cell viability, but also inhibiting 
angiogenesis by affecting angiogenic mediators downstream of hyperactive β-catenin.  
Since β-catenin signaling can become activated due to many mechanisms, its inhibition 
from any antisense modality may have therapeutic benefit. We have shown both γGPNA and 
LNA have anti-HCC effect through induction of cell death, inhibition of proliferation, anti-tumor 
angiogenesis effects, and eventually increased regression of disease. Antisense technology also 
has an added benefit in that it can be customized and made very specific to a gene of interest. 
Both γGPNA and LNA have the potential to be targeted specifically against a mutation leading 
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to β-catenin activation in HCC. Clinically, there are specific β-catenin gene mutations observed 
that affect only a single allele (163). Antisense has the potential to target only the mutated gene 
of interest while resulting in no off target effects against wild-type β-catenin in other organ 
systems. If a biopsy of the lesion is feasible, tissue can be tested through genetic analysis for β-
catenin gene mutation. Once the exact mutation in HCC is identified, devising an antisense 
against the specific mutation by utilizing either γGPNA or LNA technologies will be a relevant 
personalized approach. We have shown the utilization of both γGPNA and LNA, and these tools 
have the ability to passively diffuse through cellular membranes leading to significantly reduced 
toxicities which would be associated by agents used to force these oligonucleotides into cells. 
Also, because of their specificity, antisense oligonucleotides used, as a therapeutic intervention 
would show significantly less off target effects experienced by current chemotherapy. It would 
be an important task for future development to demonstrate the efficacy of these modalities to 
inhibit only the mutated β-catenin gene sequence to truly personalize treatment specific to a 
patient.  
5.4 β-CATENIN BIOMARKERS FOR PERSONALIZED MEDICINE 
The molecular basis of HCC is heterogeneous and may partially reflect the varying 
underlying etiologies such as HBV, HCV, ABF1, chronic alcohol intake or NAFLD/NASH. The 
key for personalized medicine in HCC will be to identify a subset of patients with specific 
‘driver’ mutations and target those for effective and safe treatment. Wnt/β-catenin signaling 
activation is one such mechanism of oncogenesis that appears to be critical in a major subset of 
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HCCs and developing an effective therapy will be of essence. However, can β-catenin be a 
global therapeutic target in HCC? The answer may be ‘No’ only because when hepatocyte-
specific β-catenin conditional KO were subjected to DEN-induced carcinogenesis, a paradoxical 
increase in tumor burden became evident, which was associated with increased injury, 
inflammation, fibrosis and oxidative stress (317). Thus β-catenin should be targeted only when 
there is evidence of its activation. Thus specific biomarkers of aberrant β-catenin signaling in 
HCC are required to accurately diagnose a subset of HCCs that clearly demonstrate its 
activation. To date, the only effective way of identifying mutation is by genetic analysis of tumor 
upon its excision. Also, β-catenin activity is identifiable through analysis of biopsy by IHC 
(192). Others and we have identified nuclear and cytoplasmic β-catenin localization as well as 
tumor-wide staining of GS, which is a good indicator of aberrant Wnt activation. However, 
biopsies may not be feasible in majority of HCC patients since these patients have significant 
fibrosis or cirrhosis. Thus ideal way to detect β-catenin activation in HCC for clinical use may be 
through identification of a secreted biomarker in plasma. Another innovative means may be 
through assessment of genetic mutation in circulating tumor cells that may have recapitulate 
aberrations of the primary tumor. In the current study, we were able to successfully reproduce a 
model of β-catenin-driven HCC, which can be used to identify novel biomarkers of β-catenin 
activation (173). In the future it may be possible to determine the secretome in these mice to 
identify novel biomarkers of β-catenin that may be of significance for diagnostics as well as a 
tool to assess treatment response. Similarly, circulating tumor cells will be assessed to determine 
such procedure for diagnosing β-catenin gene mutations. Thus, biomarker discovery in this 
model may have important translational implications in the clinic and may be applied to the 
patients in the future. 
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6.0  MATERIALS AND METHODS 
6.1 DEVELOPMENT OF γGPNA AND SMALL MOLECULES 
6.1.1 Oligomer Synthesis 
All Boc/Z protected PNA monomers and Boc-LArg-OH were purchased from Applied 
Biosystems and used without further purification.  All γGPNA monomers were synthesized by 
methods reported by Sahu and coworkers (277). All commercial reagents were used without 
further purification.  MALDI-TOF experiments were performed on a Perceptive Biosystems 
Voyager STR MALDI-TOF mass spectrometer using a 10 mg/ml solution of α-hydroxycinnamic 
acid in ACN-water (1:1) with 0.1% TFA. UV-Vis measurements were taken on a Varian Cary 
300 Bio spectrophotometer equipped with a thermoelectrically controlled multi-cell holder.  
All γGPNA oligomers were synthesized on solid-support according to standard protocol 
using standard Boc chemistry (330).  The oligomers were purified by reverse-phase HPLC and 
characterized by MALDI-TOF. All GPNA stock solutions were prepared using nanopure water 
and the concentrations were determined at 90°C using the following extinction coefficients for 
GPNA monomers: 13,700 M-1 cm-1 (A), 6,600 M-1 cm-1 (C), 11,700 M-1 cm-1 (G), and 8,600 M-1 
cm-1 (T). 
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6.1.2 Small Molecule Similarity Search 
The structural similarity is a similarity technique dependent only on surface shape and 
charge characteristics of ligands (331). Structural similarity is defined as a Gaussian function of 
the differences in the molecular surface distances of two molecules at weighted observation 
points on a uniform grid. The computed surface distances include both distances to the nearest 
atomic surface and distances to donor and acceptor surfaces. This function is dependent on the 
relative alignment of the molecules, and consequently their alignment and conformation must be 
optimized. The conformational optimization problem is solved by fragmentation, conformational 
search, alignment, and scoring, followed by incremental reconstruction from high-scoring 
aligned fragments. The alignment problem is addressed by exploiting the fact that two unaligned 
molecules or molecular fragments that have some degree of similarity will have some 
corresponding set of observers that are seeing the same things. Optimization of the similarity of 
two unaligned molecules or molecular fragments is enabled by finding similar sets of observers 
of each molecule that form triangles of the same size (331).  
6.1.3 In silico ADME and toxicity screening of projected SMs 
Computational modeling tools were used to estimate the bioavailability, aqueous 
solubility, blood brain barrier potential, human intestinal absorption, the cytochrome P450 (i.e. 
CYP2D6) enzyme inhibition potential, mutagenicity, and hERG inhibition of the hits obtained 
from the database screening. The bioavailability, aqueous solubility, and human intestinal 
absorption were estimated using the Advanced Chemistry Development, Inc. 
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(ACD/Labs)/ADME Boxes software while mutagenicity, hERG and CYP2D6 inhibition were 
estimated with ACD/Tox screening (ACD Labs, Toronto, Canada) (15). 
6.2 CELL CULTURE AND ASSAYS 
3 x 105 (per 6 well) or 4 x 104 (per 24 well) HepG2 hepatoblastoma cells and Huh7 adult 
HCC cells acquired from American Type Culture Collection (ATCC) were cultured in EMEM 
(ATCC) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals). 3 x 105 (per 6 
well) 4 x 104 (per 24 well) Snu-449 and Snu-398 adult HCC cells (ATCC) were cultured in 
RPMI-1640 (ATCC) supplemented with 10% FBS. SK-Hep1 hepatic adenoma tumor associated 
endothelial cells (ATCC) were maintained in EMEM with 10% FBS.  
6.2.1 Human HCC cell culture and establishing stable β-catenin mutants 
Human HCC cell line Hep3B (ATCC) were plated in six-well plates and cultured in 
EMEM (ATCC) supplemented with 10% FBS (Atlanta Biologicals) at 37°C in a humidified 5% 
carbon dioxide atmosphere. Wild type β-catenin gene (WT) or β-catenin gene mutated at serine 
33 to tyrosine (S33Y), which is constitutively active, were kindly provided by Dr. Jian Yu 
(Department of Pathology, Hillman Cancer Center, University of Pittsburgh, PA). The cells were 
grown to 90% confluence, 2 µg of WT and S33Y β-catenin plasmid DNA was transfected with 
Lipofectamine™ 2000 (Invitrogen), as the manufacturer's instructions. 48 hours after 
transfection, the cells were selected by multiple passaging using Geneticin (G418; Sigma; 500 
µg/ml) to generate stable transfected cell lines. 
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For transient transfection, Huh7 human HCC cells (ATCC) were plated in 6 well plates 
and transfected using 5 µl of FuGene HD (Roche) per well with either WT or S33Y β-catenin in 
normal EMEM (ATCC) containing 10% FBS (Atlanta Biologicals). Cells were incubated in 
transfection reaction overnight at 37oC, and after 24 hours, the media was changed to serum free 
EMEM and cells allowed to grow for additional 48 hours.  
6.2.2 Preparation and Cell Culture Treatments 
PMED-1 and PMED-2 (TimTec or Chembridge) were reconstituted in DMSO (Fisher-
Scientific) to 50 mM stocks. Treatment concentrations ranging from 200 µM to 25 µM were 
serially diluted in respective culture media along with corrected DMSO percentage control. 
Single treatments were either for 24 or 48 hours. After synthesis, MM, T1, or T2 γGPNA were 
reconstituted in dH2O. HCC cells were treated with γGPNA at concentrations ranging from 10 
µM to 250 nM from 24 to 72 hours. EZN-3892 and EZN-3046 LNA were provided by Enzon 
Pharmaceuticals. LNAs were reconstituted in HBSS (Lonza) followed by sterile filtration 
through a 10 µm PES filter (Millipore). Concentrations of LNA were determined using a U/V 
spectrophotometer.. 
6.2.3 Kinase Assays 
Kinase assays were performed assessing activity of PMED-1 against AKT, protein 
kinase D (PKD), Polo like kinase 1 (Plk1) and Plk2, and cyclin-dependent kinase-activating 
kinase (CAK). Black (FP) and white (TR-Fret) opaque small volume plates were purchased from 
Greiner (Monroe, NC).  IMAP binding reagent, binding buffer, terbium, peptide substrates  
 115 
(AKT: 5FAM-GRPRTSSFAEG-COOH; PKD: 5FAM-KKLNRTLSVA-COOH; Plk1 and CAK: 
5FAM-KKRNRRLSVA-OH; Plk2: 5FAM-LKKLTRRPSFSAQ-COOH), and kinase reaction 
buffers (10 mM Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 1 mM DTT and ‘carrier’ (PKD, 
AKT: 0.1% bovine serum albumin; Plk1, Plk2, CAK: 0.01% Tween-20) were purchased from 
Molecular Devices (Sunnyvale, CA).  Active Plk1 and AKT were from Cell Signaling 
Technologies ; PKD and CAK from Upstate; and Plk2 from Invitrogen.  ATP was purchased 
from GE Healthcare (Piscataway, NJ); and H89 from EMD Biosciences. 
Compounds were solubilized in DMSO to stock 10 mM and then diluted to 3x starting 
concentration 300 µM (3% DMSO) and serially diluted in 3% DMSO-water.  Briefly, 2 µL of 
3x concentration substrate + ATP in 2x complete reaction buffer were added to each well of a 
microtiter plate.  Following 2 µL additions of 3x concentration compound, 2 µL of 3x 
concentration enzyme in 1x complete reaction buffer was added to start the 6 µL total volume 
kinase reaction.  At the designated time, the reaction was stopped by addition of binding solution 
containing the binding reagent (FP) or binding reagent + terbium (TR-Fret assays).  Plates were 
read (FP Ex485/Em525 or TR-Fret Ex330 Em490, 520) on a Molecular Devices Spectramax M5. 
Specific reactions are summarized below: 
6.2.3.1 IMAP-based Plk2 TR-Fret Assay 
0.34 mUnits/µL Plk2; 550 nM substrate peptide; 35 µM ATP; 1% DMSO; 2.5 hour 
kinase reaction; 15 µl binding solution (70% A, 30% B + 1/600 binding reagent + 1/400 
terbium); 2 hour binding incubation. 
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6.2.3.2 IMAP-based PKD FP Assay 
 0.06 mUnits/µL PKD; 100 nM substrate peptide; 20 µM ATP; 1% DMSO; 90 minute 
kinase reaction; 18 µL binding solution (100% A + 1/400 binding reagent); 2 hour binding 
incubation. 
6.2.3.3 IMAP-based Plk1 TR-Fret Assay  
0.034 mUnits/µL Plk1; 750nM substrate peptide; 25 µM ATP; 1% DMSO; 3 hour kinase 
reaction; 18 µL binding solution (70% A, 30% B + 1/600 binding reagent + 1/400 terbium); 5 
hour binding incubation. 
6.2.3.4 IMAP-based CAK TR-Fret Assay  
0.1 mUnits/µL CAK; 500 nM substrate peptide; 25 µM ATP; 1% DMSO; 3 hour kinase 
reaction; 12 µL binding solution (70% A, 30% B+ 1/600 binding reagent + 1/400 terbium). 
6.2.3.5 IMAP-based AKT FP assay  
0.05 mUnits/µL AKT; 300 nM substrate peptide; 10 µM ATP; 1% DMSO; 90 minute 
kinase reaction; 18 µL binding solution (75% A, 25% B + 1/400 binding reagent); 45 minute 
binding incubation. 
6.2.4 Transient Inhibition of β-catenin via siRNA 
HepG2 cells cultured in 6 well plates were serum starved for 4 hours prior to addition of 
transfection reaction composed of Lipofectamine 2000 (3 µl) (Invitrogen), OPTIMEM (100 µl), 
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and 50 nanomoles of either CTNNB1 or negative control siRNA per well. Reaction occurred for 
4 hours at 37oC followed by addition of EMEM containing 4% FBS to cells which were 
incubated overnight. This was followed by complete replacement of media with EMEM 
containing 10% FBS. After 48 hours of transfection, cells were harvested.  
6.2.5 β-Catenin Luciferase Activity Assay 
HCC cells were transfected using FuGene (Roche) with both Renilla luciferase and 
TOPFlash firefly luciferase plasmids together at the same time. Cells were treated with T1, T2, 
or MM γGPNA 15 minutes after transfection for an additional 24 or 72 hours, whereas cells 
were treated with SMs PMED-1, PMED-2, ICG-001 or DMSO control 24 hours after 
transfection for an additional 24 or 48 hours. Lysates were then harvested using the Dual-
Luciferase Reporter Assay System (Promega). Luciferase signals were normalized to Renilla as 
transfection controls. Student’s t-test was used to determine the significance of the differences 
between treatments and p<0.05 was considered significant and of p<0.01 was considered highly 
significant. 
6.2.6 β-Catenin Luciferase Activity Assay: Time Course 
S33Y-β-catenin stably-transfected Hep3B cells were cultured in serum free EMEM 
containing 500 µg/ml G418 for 4 hours prior to Lipofectamine 2000 cotransfection using Renilla 
and TOPFlash luciferase plasmids for 4 hours. Cells were then exposed to EMEM containing 4% 
FBS and 500 µg/ml G418 overnight. The following morning, cells were serum starved again for 
4 hours in order to synchronize cell cycle followed by treatment with either 0.05% DMSO or 25 
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µM PMED-1 in EMEM containing 10% FBS and 500 µg/ml G418 for 3, 6, 9, 12, 18, 24, 36, or 
48 hours prior to harvest and analysis of samples for luciferase activity as described. 
6.2.7 MTT Assay for Toxicity 
HCC cells were plated in 6 well plates while primary human hepatocytes were plated in 
12 well plates for 24 hours. Cells were then treated with MM, T1, DMSO, PMED-1 or PMED-
2. After incubation, cultures were changed into 1% MTT (Sigma-Aldrich) wt/v in PBS for 0.5 
hours at 37oC. Cells are then lysed using room temperature isopropanol. Samples were finally 
read at 570 nm for colorometric assessment. 
6.2.8 Thymidine Incorporation Proliferation Assay 
HepG2 or Snu-398 cells were plated in 6 well plates for 24 hours. Cells were then treated 
with γGPNA for 72 hours while pulsed with 2.5 µCi of [5’-3H]-Thymidine (PerkinElmer) for 48 
hours. For SMs, cells were treated with DMSO or PMED-1 for 24 or 72 hours in the presence of 
2.5 µCi of [5’-3H]-Thymidine. Media was aspirated and washed with 1x PBS and incubated with 
5% Trichloroacetic acid (Sigma-Aldrich) for 15 minutes at 4oC. Plates were next washed in 
running water and placed to dry at 37oC. Cells were then lysed in 0.33 N NaOH for 20 minutes at 
room temperature. Samples were combined with scintillation fluid and measured in Beckman LS 
6000 IC scintillation counter. 
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6.3 PROTEIN EXTRACTION AND WESTERN BLOTTING 
6.3.1 Whole Cell Lysate Preparation: Cell Culture 
Whole cell lysates (WCL) were prepared using Radio immunoprecipitation assay (RIPA) 
buffer containing 1% IgePAL CA-630, 0.5% Sodium Deoxycholate, 0.1% Sodium dodecyl 
sulfate in 1x Phosphate Buffered Saline (PBS) after γGPNA, SM or LNA treatments. 200 µl or 
100 µl of RIPA was used per 100 mm dish or 6 well plate, respectively, with 
phosphatase/protease cocktail inhibitor (Sigma Aldrich). Plates were incubated on ice for 30 
minutes followed by removal of lysates to a fresh 1.5 ml tube. Lysates were centrifuged at 
14,000 RPM for 10 minutes at 4oC in order to remove clear supernatant to a new 1.5 ml tube 
while disposing of the pellet. Samples were then stored at -80oC until utilization or determination 
of protein concentration via BCA protein assay (Pierce) to ensure equal protein concentrations 
for subsequent assays. 
6.3.2 Whole Cell Lysate Preparation: Whole Liver Tissue 
At time of harvest, mice were anesthetized by isoflurane inhalation and subsequently 
killed by cervical dislocation. After sacrifice, the livers were extracted, washed in PBS, and then 
the tissue was flash frozen in liquid nitrogen and stored at -80oC until use. At time of use, tissue 
was homogenized in RIPA with protease/phosphatase inhibitor manually via glass mortar and 
pestle on ice. Lysates were removed to a fresh 1.5 ml tube and centrifuged at 14,000 RPM for 10 
minutes at 4oC in order to remove clear supernatant to a new 1.5 ml tube while disposing of the 
pellet. Samples were then stored at -80oC until utilization or determination of protein 
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concentration via BCA protein assay (Pierce) to ensure equal protein concentrations for 
subsequent assays.  All animal studies were approved by University of Pittsburgh IACUC office. 
6.3.3 Western Blot Analysis 
9 to 60 µg of lysate was run on precast 7.5% or 4-14% gradient polyacrylamide gel (Bio-
Rad) at 60V for 30 minutes, then 100V for 1.5 hours. Gels were then transferred onto a 
polyvinylidene fluoride (PVDF) membrane (Millipore) for 1 hour at 4oC under 100V. 
Membranes were blocked in 5% milk (Labscientific) in Blotto [0.15M NaCl, 0.02M Tris pH 7.5, 
0.1% Tween in dH2O] for 1 hour at room temperature. Primary antibodies were diluted in 5% 
milk/Blotto and incubated on membranes overnight at 4oC. Membranes were then washed in 
Blotto for 1 hour at room temperature prior to incubation of membranes with rabbit (1:10,000), 
mouse (1:25,000), or goat (1:10,000) secondary antibodies (Millipore) for one hour. Membranes 
were again washed in Blotto for 1 hour at room temperature prior to expose to either SuperSignal 
West Pico or Femto Chemiluminescent Substrate (ThermoScientific) for 1-2 minutes at room 
temperature. The bands reflective of target proteins were viewed by autoradiography. 
6.3.4 Protein Complex Immunoprecipitation 
HepG2 cells treated with DMSO, 25 µM PMED-1, or 25 µM ICG-001 for 24 hours in 
10 cm dishes. WCLs were prepared as described and 0.25 µg of control mouse IgG (Santa Cruz) 
was used to pre-clear lysates. 2 µg of β-catenin monoclonal antibody (BD Transduction 
Laboratories) were added to 500 µg of each sample for 1 hour at 4oC while rocking. 20 ml of 
Protein A/G+Agarose beads (Santa Cruz) were added to each sample over night at 4oC on a 
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rocker. Samples were then centrifuged at 13,000 rpm for 5 minutes prior to removing the 
supernatant. Bead pellet was then washed with RIPA buffer followed by 3 additional 
centrifugations and washes. After the final wash, bead pellets of each sample were resuspended 
in 40 ml of 2x SDS buffer (Bio-Rad) and boiled at 95oC for 5 minutes. Samples were centrifuged 
one last time for 1 minute and 20 µl of samples were run on a 5% polyacrylamide gel (Bio-Rad). 
Gel was run and transferred as previously described. The membrane was probed as described 
with primary antibody for CBP and secondary αrabbit antibody (1:10,000 dilution in 1% 
milk/Blotto). West Pico chemiluminesence was used to develop the membrane as previously 
indicated. 
6.4 RNA EXTRACTION AND QRT-PCR 
RNA from HepG2 cells treated with 1 µM MM or T1 for 72 hours or transfected with β-
catenin or negative control siRNA for 48 hours was harvested using TRIzol (Invitrogen) and 
purified using a phenol-based method. RNA was DNase treated (Ambion), reverse-transcribed 
using SuperScript III (Invitrogen) cDNA synthesis kit, followed by RT-PCR for Fibroblast 
growth factor 2 (FGF2), VEGF-A and β-catenin. Primers used were: 5'-
GGCTTCTAAATGTGTTACGGATG-3' and 5'-CCCAGGTCCTGTTTTGGAT-3' for FGF2, 5'-
AGGAGGAGGGCAGAATCATCA-3' and 5'-CTCGATTGGATGGCAGTAGCT-3' for VEGF-
A, 5’-CTGGCCATATCCACCAGAGT-3’ and 5’-GAAACGGCTTTCAGTTGAGC-3’ for β-
catenin and 5’-TGCACCACCAACTGCTTAGC-3’ and 5’-GGCATGGACTGTGGTCATGAG-
3’ for GAPDH. For identification of expression changes in genes involved in angiogenesis after 
GPNA treatment, RT2 Profiler PCR Array System (SABiosciences) was used according to 
 122 
manufacturer’s instructions. Data was analyzed using web based QIAGEN RT2 Profiler PCR 
Array Data Analysis version 3.5 for DDCT and significance. 
6.5 IMAGING ANALYSIS 
6.5.1 Live Cell Imaging 
HepG2 cells plated in 6 well plates were maintained in media supplemented with either 
tetramethylrhodamine (TAMRA)-labeled T1 at 1 µM with Hoescht dye for a period of 19 hours 
or DMSO or 200 µM PMED-1 for 24 under live cell imaging. Imaging was conducted on Nikon 
Eclipse Ti live cell imager using Brightfield or DAPI and Cy3 filters.  
6.5.2 TUNEL Staining 
HepG2 cells were plated 2 x 103 in 4 well chamber slides for 24 hours prior to 1 µM 
treatment with either T1 or MM. For Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) immunohistochemistry, slides were fixed 72 hours after treatment in a 3:1 
solution of methanol/glacial acetic acid for 5 min and allowed to air-dry and detection of 
apoptotic nuclei was determined by TUNEL staining using the ApopTag peroxidase kit (Intergen 
Co., Purchase, NY). 
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6.5.3 Immunohistochemistry 
Tissue samples were embedded in paraffin and cut into 4µ sections. The slides were 
deparaffinized with xylene and graded alcohol washes from 100% to 95% finally to dH2O which 
were washed in 1xPBS. Sections were microwaved for 6 minutes twice in citrate buffer and 
allowed to cool for 30 minutes. Endogenous peroxidases were quenched with 3% hydrogen peroxide 
for 10 minutes. Slides were blocked with Super Block (UltraTek) for ten minutes before adding β-
catenin (Santa Cruz) or GS (Santa Cruz) primary antibody diluted in PBS for 1 hour at room 
temperature. Sections were washed in PBS 3x followed by horseradish-peroxidase-conjugated 
secondary αGoat (1:200) or αRabbit (1:200) antibodies (Millipore) added to the slides for 30 
minutes at room temperature. Antigen retrieval was conducted using (Vector Labs). The secondary 
antibody signal was detected with DAB (Vector Labs) and the signal was quenched with dH2O 
before counterstaining with Shandon solution (Sigma Aldrich). The slides were re-graded through the 
alcohol from 75% to 100% leading to xylene washes before mounting the cover slips with DPX 
(Fluka Labs). Negative controls were generated as above, but without the primary antibody 
incubation. Images were taken on an Axioskop 40 (Zeiss) inverted brightfield microscope.  
6.5.4 Hematoxylin and Eosin Staining 
Tissue sections were cut, prepared and deparaffinized as previously indicated in section 
5.5.3. Slides were then incubated in Eosin stain for 30 seconds followed by 2 washes in 95% 
ethanol and 2 washes of 100% ethanol. Slides were then counterstained in Shandon solution for 1 
minute followed by re-grading in alcohol from 75% to 100% leading to xylene washes before 
mounting the cover slips with DPX. 
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6.5.5 Immunofluorescence 
 For detection of cells in S-phase of cell cycle, immunofluorescence for Ki-67 was 
performed. Briefly, after DMSO, PMED-1, T1, MM or no treatment control HepG2 cells were 
grown 2 x 103 in 4 well chamber slides which were fixed in 4% paraformaldehyde. Wells were 
washed with 1x PBS and cells permeabilized with 0.1% Triton-X in PBS followed by washes in 
PBS alone and then and 0.5% bovine serum albumin (BSA) in PBS (PBB). Samples were 
blocked in 2% PBB for 1 hour, washed with 0.5% PBB and incubated in 0.5% PBB containing 
primary antibody for  Ki-67 for 1 hour. After washing in 0.5% PBB, secondary antibodies-
αMouse-Alexa488 and αGoat-Alexa555, made 1:1000 in 0.5% PBB was applied to each well 
except negative control for 1 hour. Wells were washed with 0.5% PBB, then with 1x PBS wash 
and subsequently stained with Hoescht dye for 30 seconds. Samples were cover-slipped and 
imaged using Nikon Eclipse Ti live cell imager. 
6.6  ENDOTHELIAL ASSAYS 
6.6.1 In vitro Endothelial Spheroid Assay 
Serum free EMEM was used to create a 1.2% methocel stock solution using 4,000 
centipoise methyl cellulose (Sigma). SK-Hep1 cells were trypsinized, counted and resuspended 
in a 20:80 ratio of 1.2% methocel stock:growth media. Cells were then seeded at approximately 
3000 cells/well in non-adhesive, round bottom 96 well plates (Greiner bio-one) and grown for 6 
days. Keeping everything on ice, rat-tail collagen and 10x MEM (Sigma-Aldrich) was mixed 9:1 
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respectively. Collagen mixture was then conditioned with Gentamycin (0.1% v/v), Insulin (1.0% 
v/v), and 3.5% NaOH (0.5% v/v). 250 µl of collagen mixture was added per well to a 12 well 
plate and set at 37oC for 30 minutes for polymerization. After polymerization, residual media 
was removed via manual pipetting. SK-Hep1 spheroids were seeded on top of collagen gels and 
allowed to attach at 37oC for 30 minutes. Residual media was then removed again in order to lay 
a final 250 µl of collagen on top of the attached spheroids and allowed to polymerize at 37oC for 
an additional 30 minutes. After polymerization, 100 µl conditioned media from HepG2 cells 
treated with either 1 µM MM or T1 γGPNA for 72 hours was mixed with 100 µl serum free 
EMEM. Media was placed on top of the polymerized collagen sandwiches and incubated at 37oC 
under ambient oxygen, levels and 5.0% CO2 for 24 hours. Images were taken using Nikon 
Eclipse Ti live cell imager. The number of tube sprouts and the length of the tubes from each 
spheroid were counted and averaged. Three spheroids from MM and four from T1-treated group 
were utilized for assessing tube sprout numbers and tube length. Using Nikon Elements software, 
a comparison of averages (+/-SD) was made and significance assessed by student t test and 
p<0.05 was considered significant and p<0.01 was considered highly significant. 
6.6.2 In vitro Tubulogenesis Assay  
 Tubulogenesis assay was conducted using In Vitro Angiogenesis Assay Kit 
(Millipore). 25 µl of cold extracellular matrix was added to a 96 well plate (BD Falcon) and 
placed at 37oC for 1 hour. SK-Hep1 cells were seeded at 8 x 103 cells per well after being 
resuspended in respective conditioned media (HepG2 conditioned media collected after 72 hour 
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treatment with either No Treatment, 1 µM MM, or T1). Cells were incubated at 37oC for 3 hours 
prior to imaging under phase contrast using Nikon Eclipse Ti live cell imager.  
To test if the conditioned media used for in vitro spheroid assay or tubulogenesis assay 
could have any remnant unused γGPNA especially T1, the conditioned media used for these 
assays from MM or T1 γGPNA treated HepG2 cells for 72 hours was applied to fresh HepG2 
transfected using FuGene with TOPFlash and Renilla plasmids as indicated previously for 24 
hours and harvested for the luciferase assay as indicated earlier. 
6.7 ANIMAL MODEL UTILIZATION 
6.7.1 Mouse Model Development 
All animal experiments were performed under the guidelines of the National Institutes of 
Health and the Institutional Animal Use and Care Committee at the University of Pittsburgh. The 
studies performed in the current report were approved by the Institutional Animal Use and Care 
Committee at the University of Pittsburgh. 6 week old C3H/He mice (Jackson Labs) were injected 
intraperitoneally with 90 µg/g DEN (Sigma-Aldrich). Three weeks following the injection, mice 
were fed a diet containing 0.05% Phenobarbital-Sodium Salt (LabDiet) for the duration of the 
experiment, which ranged from 24-32 weeks. 
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6.7.2 LNA Administration In Vivo 
EZN-3046 (Scrambled Survivin Control) or EZN-3892 (β-catenin) LNA antisense was 
injected intraperitoneally at either 0.03 or 15 mg/kg ten times every other day in either Wild-
Type or DP mice. Mice were monitored for toxicity during course of injection period. 
6.7.3 Zebrafish experiments 
Embryos and adult fish were raised and maintained under standard laboratory conditions 
(332); we used the Tg(OTM:d2EGFP) line to assess Wnt/β-catenin signaling in vivo (258).  A 5 
mM stock of PMED-1 and a 10 mM stock of XAV939 (Cayman Chemical) were prepared in 
100% DMSO and diluted to 15 and 10 µM, respectively, with egg water supplemented with 0.2 
mM 1-phenyl-2-thiourea (Sigma-Aldrich).  As a control, 0.5% DMSO solution in the egg water 
was used.  For photography, embryos were anesthetized with 0.16 mg/ml tricaine (Sigma-
Aldrich) and mounted in egg water containing 3% methyl cellulose (Sigma-Aldrich); a Leica 
M205 FA epifluorescence microscope was used to obtain bright field and GFP fluorescence 
images. 
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APPENDIX A 
ANTIBODIES 
Table 1. Antibodies used for WB, IP, IF and IHC 
Protein Antibody Species 
Size 
(kDa) 
WB 
Dilute 
IP 
Dilute 
IF/IHC 
Dilute Company 
Product 
Number 
β-actin Mouse 42 1:2500 - - Millipore MAB1501 
β-catenin Mouse 92 1:1000 1:50 1:500 BD 610154 
c-myc Rabbit 67 1:200 - - Santa Cruz sc-42 
CBP Rabbit 265 1:100 - - Santa Cruz sc-369 
Conductin/Axin2 Goat 97 1:200 - - Santa Cruz sc-8570 
Cyclin-D1 Rabbit 36 1:200 - - Neomarkers RB-9041 
GAPDH Rabbit 37 1:800 - - Santa Cruz sc-25778 
Glutamine 
Synthetase Rabbit 49 1:200 - 1:200 Santa Cruz sc-9067 
Ki-67 Mouse - - - 1:100 Abcam Ab833 
SMP30/Regucalcin Mouse 35 1:200 - - Santa Cruz sc-130344 
VEGF-A Rabbit 42 1:200 - - Santa Cruz sc-152 
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APPENDIX B 
LIST OF IDENTIFIED SMALL MOLECULES 
Table 2. SM structures and ZINC IDs 
 
ZINC00028435 (PMED-1) 
 
 
ZINC00036110 (PMED-2) 
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ZINC00036540 
 
 
ZINC00036861 
 
 
ZINC00038222 
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ZINC00038356 
 
 
ZINC00043304 
 
ZINC00045362 
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ZINC00046955 
 
 
ZINC00050733 
 
 
ZINC00051170 
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ZINC00052109 
 
 
ZINC00053871 
 
 
ZINC00055887 
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ZINC00060369 
 
 
ZINC00060479 
 
 
ZINC00061679 
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ZINC00062638 
 
 
ZINC00069134 
 
 
ZINC18175653 
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APPENDIX C 
TABLE OF IN VIVO LNA ADMINISTRATION GROUPS 
Table 3. Categories of mice and LNA conditions 
Group LNA 
Administration 
DEN+PB 
Present 
Dose (mg/kg) n 
WTC ENZ-3046 No 15 3 
WTβ ENZ-3892 No 15 3 
DP None Yes 0 5 
DPC ENZ-3046 Yes 15 7 
DPCL ENZ-3046 Yes 0.03 5 
DPβ ENZ-3892 Yes 15 8 
DPβL ENZ-3892 Yes 0.03 4 
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